Linear epitopes of SARS-CoV-2 spike protein elicit neutralizing antibodies in COVID-19 patients

Yang Li^{1#}, Dan-yun Lai^{1#}, Hai-nan Zhang^{1#}, He-wei Jiang^{1#}, Xiao-long Tian^{2#}, Ming-liang Ma¹, Huan Qi¹, Qing-feng Meng¹, Shu-juan Guo¹, Yan-ling Wu², Wei Wang³, Xiao Yang⁴, Da-wei Shi⁵, Jun-biao Dai⁶, Tian-lei Ying^{2*}, Jie Zhou^{3*}, Sheng-ce Tao^{1*}

¹Shanghai Center for Systems Biomedicine, Key Laboratory of Systems Biomedicine (Ministry of

Education), Shanghai Jiao Tong University, Shanghai 200240, China

²MOE/NHC/CAMS Key Laboratory of Medical Molecular Virology, School of Basic Medical

Sciences, Shanghai Medical College, Fudan University, Shanghai 200032, China

³Foshan Fourth People's Hospital, Foshan 528000, China

⁴Key Laboratory of RNA Biology, Institute of Biophysics, Chinese Academy of Sciences, Beijing,

100101, China.

⁵National Institutes for Food and Drug Control, Tiantan Xili #2, Beijing, China.

⁶CAS Key Laboratory of Quantitative Engineering Biology, Guangdong Provincial Key Laboratory of Synthetic Genomics and Shenzhen Key Laboratory of Synthetic Genomics, Shenzhen Institute of Synthetic Biology, Shenzhen Institutes of Advanced Technology, Chinese Academy of Sciences, Shenzhen, China.

[#] These authors contributed equally to this work.

***Corresponding:** <u>taosc@sjtu.edu.cn</u> (S.-C. Tao) ; <u>zjet65@163.com</u> (J. Zhou); <u>tlying@fudan.edu.cn</u> (T.-L. Ying)

Abstract

SARS-CoV-2 outbreak is a world-wide pandemic. The Spike protein plays central role in cell entry of the virus, and triggers significant immuno-response. Our understanding of the immune-response against S protein is still very limited. Herein, we constructed a peptide microarray and analyzed 55 convalescent sera, three areas with rich linear epitopes were identified. Potent neutralizing antibodies enriched from sera by 3 peptides, which do not belong to RBD were revealed.

COVID-19 is caused by SARS-CoV-2^{1,2}. By June 8th, 2020, globally, 7,007,948 diagnosed cases, 402,709 deaths were reported (<u>https://coronavirus.jhu.edu/map.html</u>)³.

High titer of Spike protein (S protein) specific antibodies is in the blood of COVID-19 patients, especially IgG for both SARS-CoV⁴ and SARS-CoV-2^{5,6}. Because of the central role that S protein plays in the entry of virus to the host cell, S1 and more specific, RBD (Receptor Binding Domain) is the most-focused target for the development of COVID-19 therapeutic antibodies^{7,8} and vaccines⁹. It is known that besides RBD, other areas/ epitopes of S protein may also elicit neutralization antibodies¹⁰. However, antibody responses to full length S protein at epitope resolution has not been investigated and the capability of linear epitopes to elicit neutralizing antibody is still not explored.

To precisely decipher the B cell linear epitopes of S protein, we constructed a peptide microarray. A total of 211 peptides (Extended Data Table 1) were synthesized and conjugated to BSA. (Extended Data Fig.1a-c). The conjugates along with control proteins were printed in triplicate, and with three dilutions. High reproducibility among triplicated spots or repeated arrays for serum profiling were achieved (Extended Data Fig.1d-e). The peptides with variant concentrations may enable dynamical detection of antibody responses and indicate the antibodies against different epitopes may have different kinetic characteristics (Extended Data Fig.1f, Extended Data Fig.2a). Moreover, inhibitory assay using free peptides verified the specificity of the signals generated against the peptides (Extended Data Fig.2b).

Fifty-five sera from convalescent COVID-19 patients and 18 control sera (Extended Data Table 2) were screened on the peptide microarray for both IgG and IgM responses (Fig. 1a and Extended Data Fig. 3). For IgG, COVID-19 patients were completely

separated from controls, distinct and specific signals were shown for some peptides. In contrast, it was not distinct enough for IgM responses. We then focused on IgG for further analysis. Epitope map of S protein were generated based on the response frequency (**Fig.1b**).

Majorly, there are three hot epitope areas across S protein. The first is on CTD (C Terminal Domain) that immediately follows RBD, i.e. from S1-93 to S1-113. Interestingly, the identified epitopes, S1-93, 97, 100/101, 105/106, 111 and 113 locate predominantly at flexible loops (Fig. 1c). In addition, the signals of some epitopes had moderate correlations with others (Fig. 1e), and most of these epitopes were positively correlated with S1 (Extended Data Fig. 4c-f. The second hot area is from S2-14 to S2-23, including the FP (Fusion Peptide, aa788-806) region and the S2'cleave site (R815) (Fig. 1d). In contrary to the first hot region, the antibody responses against epitopes of this region had poor correlations among each other (Fig. 1f), possibly due to the capability of this region to generate continuous but competitive epitopes. Moreover, part of this area is shielded by other parts in trimeric S (Fig. 1d), suggesting this part would be easily accessed by immune system after the depart of S2 from S1. The third hot area is S2-78 or aa1148-1159, connecting HR1 (Heptad Repeat 1) and HR2 (Heptad Repeat 2) on S2 subunit. IgG antibodies against this epitope can be detected in about 90% COVID-19 patients, indicating it is an extremely dominant epitope. Except for these three areas, S2-34 (aa884-895) and S2-96/97 (1256-1273) also elicited antibodies in some patients. Overall, the epitope pattern of SARS-CoV-2 S protein is similar to that of SARS-CoV¹¹ (Fig. 1g).

RBD can elicit high titer of antibodies and highly correlates with that of S1 protein ⁶ (Extended Data Fig.4a), suggesting RBD is a dominant region. A peptide, S1-82, locates

exactly on the surface of RBM (Receptor Binding Motif) (Extended Data Fig 5a), was identified as an epitope. However, further analysis demonstrated that the epitope had a poor specificity (Fig. 2a, Extended Data Fig 5a), probably due to the sequence similarity (Extended Data Fig.5c-g). Thus the validity of epitope S1-82 may need further investigation. Besides S1-82, no significant binding was observed for the rest of peptides locate at RBD, suggesting that conformational epitopes are dominant for RBD.

Besides RBD, other areas/ epitopes of S protein may also elicit neutralization antibodies¹⁰. To explore this possibility, we chose 6 representative epitopes, *i.e.* S1-82, S1-93, S1-105, S1-113, S2-22 and S2-78 to test (**Fig. 2a**). Antibodies that specifically bind these epitopes were separately enriched from five sera. High specificity of these antibodies, except for S1-82, were demonstrated (**Fig. 2b, Extended Data Fig.6**). Pseudotyped virus neutralization assay with the enriched antibodies was then performed. Because of the limited amount of the enriched epitope-specific antibodies, the assay was performed for only a single point with the highest antibody concentration that was applicable for each epitope-specific antibody. Surprisingly, the antibodies against three epitopes, *i.e.*, S1-93, S1-105 and S2-78 exhibited potent neutralizing activity with a 51%, 35%, 35% virus infection inhibitory efficiency at 8.3, 10.4 and 21 μ g/mL, respectively (**Fig. 2c**). While not for S1-82, S1-113 and S2-22 at 2.6, 7.6 and 21 μ g/mL, respectively.

S1-93 locates at CTD of S1. The antibody against this epitope has neutralizing activity, which is consistent with a recent study¹², antibody binds this epitope may affect the conformation change of S for ACE2 binding. S1-105 also belongs to the CTD but close to the S1/S2 cleavage site. The antibodies may block effective protease cleavage on this site, which is critical for the entry of the virus. S2-78 locates adjacent to HR2, antibodies bind

to this epitope may interfere the formation of 6-HB (Helical Bundle), an essential structure for cell membrane fusion¹³.

Potent neutralizing antibodies could provide therapeutic and prophylactic reagents to fight against the COVID-19 pandemic¹¹. However, it is risky to only focus on the RBD region, evolutionary pressure on this "hot" area may cause potential mutations in this region. This may by pass or defect the effectiveness of the RBD region centered therapeutic antibodies and vaccines in the developing pipeline¹⁴. Thus identification of other domains or epitopes that can elicit neutralizing antibodies is essential as well. Combination of the potent antigenicity of these peptides and neutralizing activity of the corresponding antibodies makes these epitopes potential candidates for both therapeutic antibodies and vaccine development.

There are some limitations in this study. Because of very limited amount of purified antibodies could be enriched from valuable serum samples, we cannot perform a full set of neutralization assay by serial dilution to obtain the exact IC₅₀. The IC₅₀ estimated based on present data was 5-20 μ g/mL for the antibodies. However, monoclonal antibodies presumably have a better neutralization activity, so it is an option to acquire the reactive B cell clone and express recombinant monoclonal antibodies^{2,7}. Because of the poor availability of the convalescent sera, we did not thoroughly examine all the peptides that may potentially raise neutralizing antibodies. The other epitopes raised antibodies may also have neutralizing activities, such as S1-97, which is very closed to S1-93, or the peptides derived from the FP region, such as S2-18,19,20, which worth further investigation.

References

- Zhou, P. *et al.* A pneumonia outbreak associated with a new coronavirus of probable bat origin.
 Nature 579, 270–273 (2020).
- Wu, F. *et al.* A new coronavirus associated with human respiratory disease in China. *Nature* 579, 265–269 (2020).
- Dong, E., Du, H. & Gardner, L. An interactive web-based dashboard to track COVID-19 in real time. *The Lancet Infectious Diseases* 20, 533–534 (2020).
- Li, G., Chen, X. & Xu, A. Profile of specific antibodies to the SARS-associated coronavirus. *New England Journal of Medicine* 349, 508–509 (2003).
- Long, Q. X. et al. Antibody responses to SARS-CoV-2 in patients with COVID-19. Nature Medicine https://doi.org/10.1038/s41591-020-0897-1 (2020).
- Jiang, H. *et al.* Global profiling of SARS-CoV-2 specific IgG/ IgM responses of convalescents using a proteome microarray. *medRxiv* https://doi.org/10.1101/2020.03.20.20039495. (2020).
- Cao, Y. *et al.* Potent neutralizing antibodies against SARS-CoV-2 identified by high-throughput single-cell sequencing of convalescent patients' B cells. *Cell* https://doi.org/10.1016/j.cell.2020.05.025 (2020).
- Wu, Y. *et al.* Identification of Human Single-Domain Antibodies against SARS-CoV-2. *Cell Host* & *Microbe* https://doi.org/10.1016/j.chom.2020.04.023 (2020).
- 9. Amanat, F. & Krammer, F. SARS-CoV-2 Vaccines: Status Report. *Immunity* 52, 583–589 (2020).
- Chi, X. *et al.* A potent neutralizing human antibody reveals the N-terminal domain of the Spike protein of SARS-CoV-2 as a site of vulnerability. *bioRxiv* https://doi.org/10.1101/2020.05.08.083964 (2020).
- Grifoni, A. *et al.* A Sequence Homology and Bioinformatic Approach Can Predict Candidate Targets for Immune Responses to SARS-CoV-2. *Cell Host and Microbe* 27, 671-680.e2 (2020).
- Poh, C. M. *et al.* Potent neutralizing antibodies in the sera of convalescent COVID-19 patients are directed against conserved linear epitopes on the SARS-CoV-2 spike protein. *bioRxiv* https://doi.org/10.1101/2020.03.30.015461 (2020).

- Xia, S. *et al.* Inhibition of SARS-CoV-2 (previously 2019-nCoV) infection by a highly potent pancoronavirus fusion inhibitor targeting its spike protein that harbors a high capacity to mediate membrane fusion. *Cell Research* **30**, 343–355 (2020).
- Wang, L. *et al.* Importance of Neutralizing Monoclonal Antibodies Targeting Multiple Antigenic Sites on the Middle East Respiratory Syndrome Coronavirus Spike Glycoprotein To Avoid Neutralization Escape. *Journal of Virology* 92, e02002-17 (2018).

Figure Legends

Fig. 1. Linear epitope mapping of SARS-CoV-2 S protein specific antibodies by a peptide microarray, the IgG channel. a. Heatmap of IgG antibody responses of 55 sera from COVID-19 convalescent patients and controls (Healthy donors and Lung cancer patients). FI, fluorescent intensity. **b**. Epitope mapping according to the response frequency. CI, confidence interval. **c-d**. Detailed structural information of the epitopes of two hot areas on S protein (PDB: 6vyb). **e-f**, Correlations of the antibody responses among the peptides for the two hot areas. **g**. The B cell epitopes (labeled by orange rectangles) on the corresponding positions of S protein for both SARS-CoV¹¹ and SARS-CoV-2.

Fig. 2. Evaluation of neutralizing activities of epitope-specific antibodies. a. IgG responses against six selected peptides of COVID-19 patients (green) and controls (pink).
b. Peptide microarray results for the enriched epitope-specific antibodies. c. Neutralization assay with the epitope-specific antibodies. Relative infection rates for each sample to blank control are indicated.

Extended Data Fig. 1. Peptide design and microarray fabrication. a. Peptide design and conjugation with BSA through the cysteine on the N terminal. The numbers 201 and 192 indicates the peptides that were successfully synthesized and conjugated, respectively.
b. layout of the peptide microarray. The image was from anti-BSA antibody incubation.
Peptides were sequentially printed and the peptides for each row are indicated on the right.
c. A representative merged image of one COVID-19 serum. IgG response is indicated as

green, while IgM is indicated as red. **d-f.** Correlations between repeated spots of the same protein on the same array, repeats arrays and peptide groups with different concentrations.

Extended Data Fig. 2. Detection of the SARS-CoV-2 specific antibody responses by using the peptide microarray. a. Dynamic change of signal intensities for some representative peptides and S1 protein in different concentrations. b. Microarray results of the competition assays with the addition of free peptides to the sera. The serum used and the dilution are labeled above. The peptides used for competition are labeled on the left and the red arrows and white rectangles indicate the position of the corresponding peptides.

Extended Data Fig. 3. IgM responses against peptides derived from S protein. Heatmap of IgM antibody responses of 55 sera from COVID-19 convalescent patients and controls (Healthy donors and Lung cancer patients). Peptides that fully cover S protein were surveyed and S1 protein and RBD were included on the peptide microarray as controls. The peptides were sequentially arranged without clustering. FI, fluorescent intensity.

Extended Data Fig.4. Correlation analysis among antibody responses against S1 subunit derived epitopes and S1 protein. a-e. Correlations of IgG responses between two peptides, proteins or peptide and proteins. **f.** Summary of the correlations of IgG responses between representative peptides and S1 protein.

Extended Data Fig.5. Cross-activity of anti-S2-82 antibodies. a. The structural position of S1-82 on S protein (PDB: 6xyb). **b.** IgM responses of S1-82 in COVID-19 patients (blue) and controls (yellow). c-f. correlations of IgG responses between S1-82 and other peptides. The red spots were samples with high IgG signals for S1-82. g. Sequence similarity among the indicated peptides with S1-82.

Extended Data Fig.6. Epitope-specific antibody depletion from sera. a. Peptide microarray results for epitope-specific antibodies. Red arrows indicate the corresponding peptides. b. Layout of the new version of the peptide microarray with 0.3 mg/mL peptides printed. c. Representative images (left) and results (right) for comparison of sera between before and after depletion of epitope specific antibodies. The positions of the corresponding peptides labeled on the left that were used for depletion are indicated by arrows.

Methods

Peptide synthesis and conjugation with BSA

The N-terminal amidated peptides were synthesized by GL Biochem, Ltd. (Shanghai, China). Each peptide was individually conjugated with BSA using Sulfo-SMCC (Thermo Fisher Scientific, MA, USA) according to the manufacture's instruction. Briefly, BSA was activated by Sulfo-SMCC in a molar ratio of 1: 30, followed by dialysis in PBS buffer. The peptide with cysteine was added in a w/w ratio of 1:1 and incubated for 2 h, followed by dialysis in PBS to remove free peptides. A few conjugates were randomly selected for examination by SDS-PAGE. For the conjugates of biotin-BSA-peptide, before conjugation, BSA was labelled with biotin by using NHS-LC-Biotin reagent (Thermo Fisher Scientific, MA, USA) with a molar ratio of 1: 5, and then activated by Sulfo-SMCC.

Peptide microarray fabrication

The peptide-BSA conjugates as well as S1 protein, RBD protein and N protein of SARS-CoV-2, along with the negative (BSA) and positive controls (anti-Human IgG and IgM antibody), were printed in triplicate on PATH substrate slide (Grace Bio-Labs, Oregon, USA) to generate identical arrays in a 1 x 7 subarray format using Super Marathon printer (Arrayjet, UK). The microarrays were stored at -80°C until use.

Patients and samples

The Institutional Ethics Review Committee of Foshan Fourth Hospital, Foshan, China approved this study and the written informed consent was obtained from each patient. COVID-19 patients were hospitalized and received treatment in Foshan Forth hospital during the period from 2020-1-25 to 2020-3-8 with variable stay time (**Extended data**

Table 2). Serum from each patient was collected on the day of hospital discharge when the standard criteria were met according to Diagnosis and Treatment Protocol for Novel Coronavirus Pneumonia (Trial Version 5), released by the National Health Commission & State Administration of Traditional Chinese Medicine. The basic criteria are the same with that in the Diagnosis and Treatment Protocol for Novel Coronavirus Pneumonia (Trial Version 7)¹. Briefly, the key points of the discharge criteria are: 1) Body temperature is back to normal for more than three days; 2) Respiratory symptoms improve obviously; 3) Pulmonary imaging shows obvious absorption of inflammation; 4) Nuclei acid tests negative twice consecutively on respiratory tract samples such as sputum and nasopharyngeal swabs (sampling interval being at least 24 hours). From 2020-2-28, standard criteria of discharge were modified by adding one item that nuclei acid tests should be negative on anal swab sample. Sera of the control group from Lung cancer patients and healthy donors were collected from Ruijin Hospital, Shanghai, China. All the sera were inactivated at 56 °C for 30 min and stored at -80°C until use.

Microarray-based serum analysis

A 7-chamber rubber gasket was mounted onto each slide to create individual chambers for the 7 identical subarrays. The microarray was used for serum profiling as described previously with minor modifications². Briefly, the arrays stored at -80°C were warmed to room temperature and then incubated in blocking buffer (3% BSA in 1×PBS buffer with 0.1% Tween 20) for 3 h. A total of 400 μ L of diluted sera or antibodies was incubated with each subarray for 2 h. The sera were diluted at 1:200 for most samples and for competition experiment, free peptides were added at a concentration of 0.25 mg/mL. For the enriched antibodies, 0.1-0.5 μ g antibodies were included in 400 μ L incubation buffer. The arrays

were washed with 1×PBST and bound antibodies were detected by incubating with Cy3conjugated goat anti-human IgG and Alexa Fluor 647-conjugated donkey anti-human IgM (Jackson ImmunoResearch, PA, USA), which were diluted for 1: 1,000 in 1×PBST. The incubation was carried out at room temperature for 1 h. The microarrays were then washed with 1×PBST and dried by centrifugation at room temperature and scanned by LuxScan 10K-A (CapitalBio Corporation, Beijing, China) with the parameters set as 95% laser power/ PMT 550 and 95% laser power/ PMT 480 for IgM and IgG, respectively. The fluorescent intensity was extracted by GenePix Pro 6.0 software (Molecular Devices, CA, USA).

Purification of epitope-specific antibodies

Depends on the availability, 200-500 µL serum from COVID-19 convalescent patient was two-fold diluted in 1×PBS and then pre-incubated with streptavidin beads to eliminate nonspecific binding. For each epitope, 100 µg peptides conjugated with biotin-BSA were coated to 100 µL streptavidin magnetic beads (Invitrogen, MA, USA) in 1×PBS buffer at room temperature for 1 h. The protein-coated streptavidin beads were washed 4 times in 1×PBS containing 0.1% BSA, and incubated with the pre-cleaned serum in 1×PBS at 4°C for 4 h. The streptavidin beads were then washed 3 times in 1×PBS containing 0.1% BSA, and eluted with 0.2 M glycine, 1 mM EGTA, pH 2.2. Finally, the antibodies were neutralized with 1M Tris-HCl, pH8.0. The concentration of the purified antibody was monitored by silver staining.

Pseudotyped Virus Neutralization

The neutralization assay was performed as described³. Briefly, 293 T cells were cotransfected with expression vectors of pcDNA3.1-SARS-CoV-2-S (encoding SARS-CoV-2 S protein) and pNL4-3.luc.RE bearing the luciferase reporter-expressing HIV-1 backbone. The supernatants containing SARS-CoV-2 pseudotyped virus were collected 48 h post-transfection. Antibodies or isotype IgG control (Thermo Fisher Scientific, MA, USA) in DMEM supplemented with 10% fetal calf serum were incubated with pseudoviruses at 37°C for 1 h and then the mixtures were added to monolayer Huh-7 cells (10⁴ per well in 96-well plates). Twelve h after infection, culture medium was refreshed and then the cells were incubated for an additional 48 h. The luciferase activity was calculated for the detection of relative light units using the Bright-Glo Luciferase Assay System (Promega, WI, USA). Huh-7 cells were subsequently lysed with 50 µl lysis reagent (Promega, WI, USA), and 30 µl of the lysates were transferred to 96-well Costar flat-bottom luminometer plates (Corning Costar, MA, USA) for the detection of relative light units using the Firefly Luciferase Assay Kit (Promega, WI, USA) and an Ultra 384 luminometer (Tecan, Switzerland).

Data analysis and software

Signal Intensity was defined as the median of the foreground subtracted by the median of background for each spot and then averaged the triplicate spots for each peptide or protein. IgG and IgM data were analyzed separately. Pearson correlation coefficient between two proteins or indicators and the corresponding p value was calculated by SPSS software

under the default parameters. Cluster analysis was performed by pheatmap package in R⁴. To calculate the response frequency of each epitope specific antibody, mean signal + 3*SD of the control sera were used to set the threshold. The epitope map was generated by ImmunomeBrowser issued by IEDB (Epitope Prediction and Analysis Tools)⁵. Visualization of the structural details were processed by Pymol (<u>https://pymol.org/2/</u>).

References

- National Health Commission & National Administration of Traditional Chinese Medicine. Diagnosis and Treatment Protocol for Novel Coronavirus Pneumonia (Trial Version 7). *Chinese medical journal* 133, 1087–1095 (2020).
- Li, Y. *et al.* Longitudinal serum autoantibody repertoire profiling identifies surgery-associated biomarkers in lung adenocarcinoma. *EBioMedicine* 53, 102674 (2020).
- Wu, Y. et al. Identification of Human Single-Domain Antibodies against SARS-CoV-2. *Cell Host & Microbe* (2020). doi:10.1016/j.chom.2020.04.023.
- R, K. Pheatmap: Pretty Heatmaps. <u>https://cran.r-project.org/web/packages/pheatmap/index.html</u> (2015).
- Dhanda, S. K. *et al.* ImmunomeBrowser: A tool to aggregate and visualize complex and heterogeneous epitopes in reference proteins. *Bioinformatics* 34, 3931–3933 (2018).

Data availability

The peptide microarray data are deposited on Protein Microarray Database (http://www.proteinmicroarray.cn) under the accession number PMDE242. Additional data related to this paper may be requested from the authors.

Acknowledgements

This work was partially supported by the National Key Research and Development Program of China Grant (No. 2016YFA0500600), National Natural Science Foundation of China (No. 31970130, 31600672, 31670831, and 31370813), Shenzhen Key Laboratory of Synthetic Genomics (ZDSYS201802061806209), Shenzhen Science and Technology Program (KQTD20180413181837372), Guangdong Provincial Key Laboratory of Synthetic Genomics (2019B030301006) and Foshan Scientific and Technological Key Project for COVID-19 (NO:2020001000430).

Author contributions

S-C. T. developed the conceptual ideas and designed the study. J. Z., W. W. and X. Y. collected the sera samples and provided key reagents. Y. L., D-Y. L., H-N. Z., X-L. T., H-W. J., M-L. M., H. Q., Q-F. M. and S-J. G. performed the experiments. T-L. Y and Y.L.-W provide critical suggestion on the neutralization assay. S-C.T. and Y. L. wrote the manuscript with suggestions from other authors. D-W. S. and J-B. D. provided key reagents or data analysis.

Competing interests

The authors declare no competing interest.







S1-105/106

(625-642)

S1-111/113

(661 - 684)

S1-100/101

0 (595-612)

S1/S2 cleavage

site



FP(788-806)

S1-106

S1-111

S1-113

0.2

0

Fig. 1. Linear epitope mapping of SARS-CoV-2 S protein specific antibodies by a peptide microarray.



a. IgG antibody responses against six representative peptides







Fig. 2. Evaluation of neutralizing activity of epitope-specific antibodies.



Extended Data Fig.1. Peptide Design and microarray fabrication

medRxiv preprint doi: https://doi.org/10.1101/2020.06.07.20125096; this version posted June 9, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
 A. Binding kinetics varies among different peptides and their corresponding serum antibodies



B. Competition of the binding by free peptides



Extended Data Fig.2. Detection of the SARS-CoV-2 specific antibody responses by using the peptide microarray



Extended Data Fig.3. IgM responses against peptides derived from spike protein



Extended Data Fig.4. Correlation analysis among antibody responses against S1 subunit derived epitopes and S1 protein.



G. Sequence similarity to S1-82

- S1-82 487 NCYFPLQSYGFQ 498
- S2-34 884 SGWTFGAGAALQ 895
- S2-43 938 LSSTASALGKLQ 949
- S2-85 1190 AKNLNESLIDLQ 1201
- S2-16 776 KNTQEVFAQVKQ 787

Extended Data Fig.5. Cross-reactivity of anti-S2-82 antibodies



B. Layout of the peptide microarray V 2.0



C. Comparison of sera before and after depletion of epitope specific antibodies



Extended Data Fig.6. Epitope-specific antibody depletion from sera

Extended Data Table 1.1	The peptides sv	vnthesized ir	າ this studv
-------------------------	-----------------	---------------	--------------

NO.	Peptide ID	Sart Position	Amino acid sequence	End Position	Note
1	S1-1	1	MFVFLVLLPLVS	12	
2	S1-2	7	LLPLVSSQCVNL	18	
3	S1-3	13		24	
4	S1-4 S1-5	19		30	
6	S1-6	31	SETRGVYYPDKV	42	
7	S1-7	37	YYPDKVFRSSVL	48	
8	S1-8	43	FRSSVLHSTQDL	54	
9	S1-9	49	HSTQDLFLPFFS	60	
10	S1-10	55	FLPFFSNVTWFH	66	Insoluble
11	S1-11 S1 12	61 67		72	
12	S1-12 S1-13	73	TNGTKREDNPVI	84	
14	S1-14	79	FDNPVLPFNDGV	90	
15	S1-15	85	PFNDGVYFASTE	96	
16	S1-16	91	YFASTEKSNIIR	102	
17	S1-17	97	KSNIIRGWIFGT	108	
18	S1-18	103	GWIFGTTLDSKT	114	
19	S1-19 S1-20	109		120	
20	S1-20	121	NNATNVVIKVCF	132	
22	S1-22	127	VIKVCEFQFCND	138	
23	S1-23	133	FQFCNDPFLGVY	144	
24	S1-24	139	PFLGVYYHKNNK	150	
25	S1-25	145	YHKNNKSWMESE	156	
26	S1-26	151	SWMESEFRVYSS	162	
27	S1-27 S1 28	157		108	
20	S1-20	169	EYVSOPELMDLE	180	
30	S1-30	175	FLMDLEGKQGNF	186	
31	S1-31	181	GKQGNFKNLREF	192	
32	S1-32	187	KNLREFVFKNID	198	Insoluble
33	S1-33	193	VFKNIDGYFKIY	204	
34	S1-34	199	GYFKIYSKHTPI	210	
30 36	S1-35 S1-36	205		210	
37	S1-37	217	POGESALEPI VD	228	
38	S1-38	223	LEPLVDLPIGIN	234	
39	S1-39	229	LPIGINITRFQT	240	
40	S1-40	235	ITRFQTLLALHR	246	Insoluble
41	S1-41	241	LLALHRSYLTPG	252	
42	S1-42	247	DSSSGWTACAAA	258	
43	S1-43 S1-44	259	TAGAAAYYVGYI	204	
45	S1-45	265	YYVGYLQPRTFL	276	
46	S1-46	271	QPRTFLLKYNEN	282	Insoluble
47	S1-47	277	LKYNENGTITDA	288	
48	S1-48	283	GTITDAVDCALD	294	
49	S1-49	289	VDCALDPLSETK	300	
5U 51	S1-50 S1_51	295 301		300	
52	S1-51	307	TVEKGIYQTSNF	318	
53	S1-53	313	YQTSNFRVQPTE	324	
54	S1-54	319	RVQPTESIVRFP	330	
55	S1-55	325	SIVRFPNITNLC	336	
56	S1-56	331	NITNLCPFGEVF	342	
57	S1-57	337	PEGEVENATREA	348	
50 50	S1-50 S1-50	343 349	SV/VAW/NRKRISN	304 360	
60	S1-60	355	RKRISNCVADYS	366	
61	S1-61	361	CVADYSVLYNSA	372	
62	S1-62	367	VLYNSASFSTFK	378	
63	S1-63	373	SFSTFKCYGVSP	384	
64	S1-64	379		390	
65	51-65	385		396	
67	S1-00 S1-67	391 397	ADSEVIRGDEVR	402 408	
68	S1-68	403	RGDEVRQIAPGQ	414	
69	S1-69	409	QIAPGQTGKIAD	420	
70	S1-70	415	TGKIADYNYKLP	426	
71	S1-71	421	YNYKLPDDFTGC	432	

73 S1-73 443 VMANSINUDSK 444 74 S1-74 439 VMLDSKVGORVN 450 75 S1-75 445 VGGNNVILVRLF 450 Insolubie 76 S1-76 451 VLVRLFRSNLK 462 Insolubie 78 S1-77 467 RKSNLKPFERDI 468 Insolubie 81 S1-78 469 STEVQAGSTPC 460 464 81 S1-81 471 ACSTFCAVCEP 462 464 81 S1-82 467 NCVFPLQSYGFQ 468 464 82 S1-83 GSTGFGPTHKVG 554 454 459 PTOVAGYQPYEV 516 85 S1-83 517 VLPSPLLHAPA 522 57 570 564 454 553 TVCQFK 554 455 562 570 562 570 562 570 563 563 570 564 456 100 51-00 564 454 450<	72	S1-72	427	DDFTGCVIAWNS	438	Failure for synthesis
174 S1-75 S1-75 Vision 450 75 S1-76 445 VUGNYNVLYRLF 450 Insoluble 76 S1-78 4451 VUSGNYNVLYRLF 466 77 S1-78 443 PFERDISTERYO 474 78 S1-78 463 PFERDISTERYO 474 80 S1-80 475 AGSTPCASUCF 480 81 S1-81 481 NOVEPROVEDF 482 82 S1-84 487 NOVEPROVENTIA 482 83 S1-85 487 NOVEPROVENTIA 482 84 S1-86 563 YOPYRVVLSFE 516 85 S1-86 571 LLHAPATVCGPK 522 86 S1-87 S1-77 LLHAPATVCGPK 524 87 S1-87 S1-71 LLHAPATVCGPK 526 91 S1-90 S24 KINCVNFNNL 546 91 S1-91 S41 PHINOLYGRKOW 540 <tr< td=""><td>73</td><td>S1-73</td><td>433</td><td>VIAWNSNNI DSK</td><td>444</td><td>·</td></tr<>	73	S1-73	433	VIAWNSNNI DSK	444	·
75 SI-76 446 V GONNYU YRUE 466 Insoluble 76 SI-76 451 Y VIVE, FRSNIK 462 77 SI-77 457 RKSNIK/FRERDI 468 78 SI-79 449 STELIVOAUSTEVO 440 79 SI-79 449 STELIVOAUSTEVO 440 80 SI-80 475 AGSTPCOVECP 480 81 SI-81 441 NVCYPEQUEVPL 480 82 SI-82 487 NVCYPEQUEVPL 510 83 SI-83 505 YQPYRVVLSFE 516 84 SI-84 523 KTURVVLSFE 540 85 SI-86 523 KITURVVKCVN 540 89 SI-89 553 TESNKKCVNE 552 92 SI-92 547 TGSNUTGVL 552 93 SI-93 553 TESNKKCVNE 556 94 SI-94 559 FLENOLTEGVL 582	74	S1-74	430		450	
10 81-76 14-10 VUXPERISALK 462 Insolube 77 S1-77 457 HKSNLKPERDI 468 78 S1-78 463 PFERDISTEIYQ 474 79 S1-78 469 STEIYQACSTPC 480 80 S1-80 475 AGSTPCNGVEGF 480 81 S1-81 481 NCVFPLQSYGFQ 482 82 S1-82 487 NCVFPLQSYGFQ 482 83 S1-83 493 QSYGFQFTNGVG 504 84 S1-84 499 PTNCVGFVFL 525 85 S1-87 CVCFPKSTNVG 534 85 S1-88 523 TVCGFKSTNV 534 89 S1-89 S54 S55 TVGGFKSTNV 534 89 S1-89 S53 TESNAKCWY 546 91 S1-91 541 PFNFOLGFRDIA 570 92 S1-92 547 PLPCOLGFRDIA 570 <	75	Q1 75	400		456	Incolubio
76 S1-76 451 VLPRLPKSNLK 462 77 S1-77 457 RKSNLKPFERD 464 78 S1-79 469 PTEVQAGSTPC 464 78 S1-79 469 PTEVQAGSTPC 464 80 S1-80 475 SCORVECFF 485 81 S1-81 481 NGVFCQVFVFU 492 82 S1-83 493 QSYGCQ-TNGVG 504 84 S1-84 499 PTINGVGVQFVFU 510 85 S1-85 505 YQPYRVVVLSFE 516 86 S1-88 523 TVCGPKVSTNLV 534 88 S1-88 523 KIKCVNNFCVNL 540 90 S1-40 531 FEPROPGRDA 570 91 S1-43 553 TESINKPLFPCQ 564 92 S1-45 565 FGFDLOTTDAV 576 94 S1-44 559 FEPROPGRDA 570 95 S1-45 565 FGFDLOTTDAV 776 96 S1-46 571 </td <td>75</td> <td>51-75</td> <td>445</td> <td></td> <td>400</td> <td>Insoluble</td>	75	51-75	445		400	Insoluble
77 S1-77 457 PRERDISTEVO 468 78 S1-79 469 STETYOAGSTPC 469 80 S1-80 473 AGSTPC/NCHEEF 469 81 S1-82 447 NCVEFPLGSYGFO 469 82 S1-83 443 NCVEFPLGSYGFO 469 84 S1-84 499 PTINGYGYOPTRV 504 85 S1-85 565 YOPTYVVVSFE 516 86 S1-85 565 YOPTYVVVSFE 516 86 S1-84 523 TVCGPKKSTNLV 534 87 S1-87 517 LHAPATVCGPK 552 90 S1-90 535 KINUKOVN 546 91 S1-91 541 PFPGQFGRUA 577 92 S1-92 547 TCGVLTESNKK 558 93 S1-93 553 TESNKRH,PFQQ 564 94 S1-44 569 FORDATTAT 576 95 S1-93 577 PDOPOTELIDIT 684 96 S1-94 57	76	S1-76	451	YLYRLFRKSNLK	462	
78 S1-78 463 PFERDISTEIYQ 474 80 S1-80 475 AGSTPC/GVECFP 489 81 S1-81 481 NOVEEPRCYFPL 482 82 S1-82 487 NOVEEPRCKYFPL 544 83 S1-83 489 CSYGEPTNEY 544 84 S1-83 489 CSYGEPTNEY 544 85 S1-83 489 CSYGEPTNEY 544 86 S1-84 S1-85 S145 S145 87 S1-87 S1-77 LIAPATVCGPK S22 87 S1-87 S1-77 TCGVLTSNKK S54 90 S1-90 S35 KIKCVNNN S40 S44 91 S1-91 S41 FINFNOLTGTGVL S52 92 S1-92 S47 TGGVLTSNKK S58 93 S1-93 S65 FGRDIADTDAV S76 94 S1-94 S65 FGRDIADTDAV S76 95 S1-95 S65 FGRDIADTDAV S76 96 S1-96 S61<	((S1-77	457	RKSNLKPFERDI	468	
79 S1-79 460 STELYQAKSTPC 480 80 S1-80 475 ACSTPCNCYFPL 482 81 S1-81 481 NCYFPLOKYFPL 482 82 S1-82 483 OCYFPLOKYFPL 482 84 S1-83 483 OCYFPLOKYFPL 514 85 S1-85 511 NCYFPLOKYFPL 512 86 S1-85 511 NCYFPLOKYFPL 513 86 S1-88 511 YUSFELLHAPA 512 87 S1-87 517 LLHAPATVCGPK 523 88 S1-88 523 TVCGPKKSTNLV 534 89 S1-80 535 KKNCVNFNFNCL 546 91 S1-91 541 FPFOOFGRDIA 577 92 S1-92 547 TGTGVLTESNKK 558 93 S1-93 563 FEBOOFGRDIA 577 94 S1-94 569 FLPTOOFGRDIA 577 95	78	S1-78	463	PFERDISTEIYQ	474	
80 S1-80 475 AGSTPC/MQVEGF 486 81 S1-81 487 NGVEGPKCYFPL 492 82 S1-82 487 NCVFPLQSYGFQ 493 83 S1-83 493 OSYGEPTRAVG 504 84 S1-84 499 PTINGVGYQPYRV 510 85 S1-85 505 YQPYRVVUSFE 518 86 S1-86 511 VUSFELLHAPA 522 87 S1-87 S11 LLHAPA 522 88 S1-88 523 TUCGPKKSTNIN 634 90 S1-99 533 TESNKKFLPFOO 564 91 S1-91 541 FINPROGROPAL 562 92 S1-93 553 TESNKKFLPFOO 564 93 S1-94 565 FGRDADTTDAV 576 94 S1-94 565 FGRDADTTDAV 576 95 S1-95 565 FGRDADTTDAV 572 96 S1-	79	S1-79	469	STEIYQAGSTPC	480	
81 S1-42 487 NCYFPLOSYGPQ 492 82 S1-43 493 CSYGPQPTNGVG 504 83 S1-43 493 CSYGPQPTNGVG 504 84 S1-44 499 PTNGVGVQPTRV 510 85 S1-45 505 YQPYRVVUSFE 515 86 S1-48 522 XVISTELLAPAA 522 87 S1-47 517 LI-HAPATVOGPK 524 88 S1-48 523 KNKCVNFNNCL 543 90 S1-49 541 FILPROLTGTGVL 552 91 S1-49 541 FILPROLTGTGVL 552 92 S1-33 555 FILPROCTGTGNU 563 93 S1-48 555 FILPROCTGNU 563 94 S1-49 565 FILPROCTORDU 563 97 S1-49 577 ROPCHELDIT 568 98 S1-49 583 EILDITPCSFG 564 98 S1-49 583 FILDITPCSFG 564 100 S1-105	80	S1-80	475	AGSTPCNGVEGF	486	
82 S1-42 487 NCVFPLQSYGP 498 83 S1-43 499 PTNGVGYQPYRV 510 84 S1-44 499 PTNGVGYQPYRV 510 85 S1-85 505 YQPYRVVUSFE 516 86 S1-46 511 VUSFELLHAPA 522 87 S1-47 517 LLHAPATCGPK 523 88 S1-48 523 TVCQFKKSTNLV 534 89 S1-90 535 KKINLVKNCVN 546 91 S1-91 541 FPNFOLCTGVL 552 92 S1-92 547 TGTGVLTESNKK 568 94 S1-94 556 FGRDDTDAV 77 96 S1-95 565 FGRDDATDAV 77 97 S1-97 577 RDPCTLEDTT 563 98 S1-98 563 ELDTPCSFG 594 98 S1-99 569 VSVTPCTNTN 606 100 S1-101	81	S1-81	481	NGVEGFNCYFPL	492	
83 S1-83 493 CSYGFOPTMGVG 504 84 S1-84 499 PTNGVGVOPYRV 510 85 S1-86 505 VOPYRVVUSFE 516 86 S1-86 511 VULSFELLHAPA 522 87 S1-87 517 LLHAPATVCGPK 528 88 S1-88 523 TVCGFKKSThLV 534 89 S1-89 522 KKTNLVKNKCVN 540 90 S1-90 535 KINKCVPNINGL 552 91 S1-91 541 FNENGLIGEROJA 570 95 S1-96 566 FGRDIADITDAV 576 96 S1-96 567 DTDAVRDPOTL 582 97 S1-97 577 RDPCIFLIDIT 588 98 S1-86 583 ELDITPCSFCG 594 99 S1-99 589 PCSFGGVSVTP 600 101 S1-101 601 GTNTSNOVAVLY 612 102	82	S1-82	487	NCYEPLOSYGEO	498	
ab C + 144 C + 169 C + 174 + 174 C + 174 + 174 84 S + 146 86 S + 146 S + 147 S + 147 S + 147 S + 147 87 S + 148 S + 148 S + 147 S + 147 S + 147 89 S + 149 S + 147 S + 147 S + 147 S + 147 90 S + 149 S + 147 TGTGVLTESNKK S + 148 91 S + 147 S + 147 S + 147 S + 147 92 S + 142 S + 147 TGTGVLTESNKK S + 148 94 S + 144 S + 147 TGTGVLTESNKK S + 148 95 S + 146 S + 140 S + 147 S + 147 96 S + 146 S + 147 S + 147 S + 148 101 S + 148 S + 147 S + 147 S + 147 102 S + 140 S + 147 S + 147 S + 147 103 S + 140 S + 147 S + 147	83	S1_83	107	OSVGEOPTNGVG	504	
B 3 1:00 Hot FV OPYRVUT REF 3 16 B6 51:80 511 VUCBYRVUT REF 516 B6 51:87 517 VUCBYRVUT REF 516 B7 51:89 517 VUCBYRVUT REF 528 B8 51:89 522 KSTNUVRNCVN 534 90 51:90 535 KINKCVPNENGL 546 91 51:91 547 TGGYUTESNKK 552 92 51:92 547 TGGYUTESNKK 558 93 51:93 555 FLPFOQG 564 94 51:94 595 FLPFOQG 564 95 51:96 565 FGRDADTTDAV 576 96 51:91 DTTDAVUPOPOTL 582 97 97 51:97 577 RDPOTLEILDIT 588 98 51:98 583 FLEDROK 564 100 51:101 601 GTNTSNOVAVLY 612 101 51:	0.0	S1-05 S1 04	400		510	
BS S1-85 S05 TUP TRVVUSTE S10 86 S1-86 S11 VULSTELLARA S22 87 S1-87 S17 LLHAPATVCGPK S23 88 S1-88 S23 TVCGPKKSTNLV S34 89 S1-89 S22 KSTNL/WINCKUN S40 90 S1-90 S35 KIKCVNNTNCL S46 91 S1-91 S41 PHENQLTGENKK S58 92 S1-83 S53 TESNKKFLEPQQ S64 94 S1-94 S55 FGRDADTDAV S76 95 S1-95 S1-97 TT RDPGTLEIDT S88 96 S1-98 S83 FGRDADTDAV S76 97 S1-97 S77 RDPGTLEIDT S88 98 S1-98 S83 PCSFGCVSVIP 606 90 S1-100 S61 QUAVICIPARIA S62 101 S1-101 601 GTINTSNOVAVLY S12 <	04	51-04	499	PINGVGIQPIRV	510	
86 S1-86 S11 VVLSFELLHAPA S22 87 S1-87 S17 LHAPATVGGPK S28 88 S1-88 S23 TVCGPKKSTNLV S34 89 S1-89 S28 KKNLVKNCVN S44 90 S1-90 S35 KKNLVKNCVN S46 91 S1-91 S41 FINEKKELFARK S68 92 S1-92 S47 TGTGVLTESTNKK S68 93 S1-93 S53 TSTSNKKFLPFOQ S64 94 S1-94 S59 FLPFQGFGRDIA S70 96 S1-96 S77 RDPQTLELDT S88 98 S1-98 S83 ELDITPCSFGG S94 99 S1-90 S89 PCSEGGVSVITP 600 101 S1-101 601 GATSNOVALY 612 102 S1-102 G07 QVAVLYODVNCT 618 103 S1-103 643 FOTRAGCLIGAE 654 104	85	S1-85	505	YQPYRVVVLSFE	516	
87 51-87 517 LLHAPATVCGPK 528 88 51-88 529 KSTNLVKNKCVN 534 89 51-89 529 KSTNLVKNKCVN 540 90 51-90 535 KIKCVNFNPGL 546 91 51-91 541 FNFNCLTESNKK 552 92 S1-93 553 TESNKKFLFPQQ 564 94 S1-94 559 FLFPCQCFGRDIA 570 95 S1-95 565 FGRDIADTTDAV 576 96 S1-96 571 DTTDAVRDPQTL 582 97 S1-97 S77 RDPQTLEILDIT 588 98 S1-88 583 ElLDIPCSG 594 99 S1-90 589 PCSFGGVSVITP 600 100 S1-101 601 GTINTSNOVAULY 612 1013 S1-103 613 QDVNCTEVPVAI 634 106 S1-106 631 POTRYSTSINSM 642 107	86	S1-86	511	VVLSFELLHAPA	522	
88 S1.88 523 TVCGPKKSTNLV 534 89 S1.89 529 KSTNLVKNCVN 540 90 S1.80 535 KINKCVNFNRGL 546 91 S1.81 S41 FNFNLGTGTVL 552 92 S1.92 547 TGTGVLTESNKK 558 93 S1.83 553 TESNKKLPFQQ 564 94 S1.94 559 FLPFQQFGRDIA 570 95 S1.95 555 FGRDADTTDA 576 96 S1.96 571 DTDAVRDPOTL 582 97 S1.97 S77 RDFQGSVTP 600 100 S1.100 505 VSUTPCITNEN 606 101 S1.110 607 QVALVQOVNCT 612 102 S1.101 613 QDVNCTEVPV4 624 106 S1.106 631 PTWRVSTGSNV 640 108 S1.106 631 PTWRVSTGSNV 642 108	87	S1-87	517	LLHAPATVCGPK	528	
89 S1-89 529 KSTNLVKNRCVN 540 90 S1-90 535 KNKCVNFNFNGL 546 91 S1-91 541 FNFNGLTGTOVL 552 92 S1-92 547 TGTGVLTESNKK 558 93 S1-93 553 TESNKKFLPFQQ 564 94 S1-94 559 FLPCOFGRDIA 570 95 S1-95 565 FGRDIADTDAV 572 96 S1-96 571 DTTDAVRDPOTL 582 97 S1-97 STOPOTLEILDIT 588 EILDITPCSFGG 594 98 S1-98 583 EILDITPCSFGG 594 99 S1-90 589 PCSEGGVSVITP 606 101 S1-101 601 GTNTSNQ/WALV 618 103 S1-105 625 HADQLTPTWRVY 630 106 S1-106 631 PTMRACQLIACA 672 107 S1-107 637 STGSNVFOTRAG 644 <td>88</td> <td>S1-88</td> <td>523</td> <td>TVCGPKKSTNLV</td> <td>534</td> <td></td>	88	S1-88	523	TVCGPKKSTNLV	534	
90 S1-90 S35 KNKCVNFNNGL 546 91 S1-91 S41 FNFNCLTGTOVL S52 92 S1-92 S47 TGTGVLTESNKK S58 93 S1-33 S53 TESNKKELPFOO S64 94 S1-94 S59 FLPFOOFGRDIA S70 95 S1-95 S56 FGRDADTTDAVRDPOTL S88 97 S1-97 RDPOTELLDT S88 98 S1-90 S95 VSUTEGTOR S64 100 S1-100 S95 VSUTEGTOR S64 101 S1-101 G01 GTNTSNOVACLYDOVCT 618 102 S1-102 G07 QCAVLYDOVCT 618 103 S1-105 G25 HADDLTPTWRVY G36 104 S1-106 G31 POTKRACLIAR 644 107 S1-107 G37 STGSNVFQTRAG 648 Insoluble 108 S1-108 643 FOTTRACLIGAE 654 109	89	S1-89	529	KSTNLVKNKCVN	540	
91 S1-01 541 FNFNCLTGTQVL 552 92 S1-92 547 TGTQVLTESNKKK 558 93 S1-93 553 TESNKKELPFOQ 564 94 S1-94 559 FLPFOQFGRDIA 570 95 S1-95 565 FGRDIADTTDAV 576 96 S1-96 571 DTDAVRDPOTL 582 97 S1-97 S77 RDPOLELIDT 588 98 S1-98 563 ELIDIPCSFGG 594 99 S1-99 589 PCSGQSVTP 600 100 S1-100 595 VSVITPCTNTSN 666 101 S1-101 601 GTNTSNOVAUV 612 102 S1-100 631 PTWRVSTGSNV 644 106 S1-106 631 PTWRVSTGSNV 644 107 S1-107 637 SYGSNVFQTRAG 644 108 S1-108 643 FOTRAGCLIGAE 654 110	90	S1-90	535	KNKCVNFNFNGL	546	
2 S1 42 S47 TGTGVLTESNKK S58 33 S1 43 S53 TESNKKE PFOO S64 44 S1 44 S59 FLPFOOFGRUA S70 95 S1 495 S65 FGEDIADTTDAVRDPOTL S52 97 S1 497 S77 RDPOTLELIDIT S82 98 S1 48 S63 ELLDITPCSFGG S94 99 S1 49 S68 PLCSFGGVSVIPP 600 100 S1 +101 G01 GTNTSNOVAULY G12 101 S1 +101 G01 GTNTSNOVAULYQDVNCT G18 103 S1 +103 G13 QDVNCTEVPVAI G24 107 S1 +106 G25 HADQLTPTWRVY G35 106 S1 +106 G37 STGSNVFQTRAG G48 Insoluble 107 S1 +107 G37 STGSNVFQTRAG G42 Insoluble 108 S1 +108 643 FOTRAGCLIGAE G54 109 S1 +106 G37	91	S1-91	541	ENENGI TGTGVI	552	
bit Display Display <thdisplay< th=""> <thdisplay< th=""> <thdispl< td=""><td>02</td><td>S1 02</td><td>547</td><td></td><td>558</td><td></td></thdispl<></thdisplay<></thdisplay<>	02	S1 02	547		558	
33 31-33 333 1ESIMAL PPOL 304 94 \$1-95 \$1-95 \$65 FIGRDIADTDAV \$70 95 \$1-95 \$65 FIGRDIADTDAV \$70 96 \$1-96 \$71 DTDAVRDPOTL \$82 97 \$1-97 \$77 RDPOTLEILDIT \$88 98 \$1-98 \$68 ELIDITPCSFGG \$94 99 \$1-99 \$69 PCSFGGVSVITP 600 100 \$1-101 601 GTNTSNQVAULY 612 102 \$1-102 607 QVAULYDDVNCT 618 103 \$1-103 613 QDVNCTEVPVAI 624 105 \$1-105 625 HADQLTPTWRVY 630 106 \$1-106 631 PTWRYSTGSNV 642 107 \$1-107 637 STGNNFQTRAG 644 Insoluble 108 \$1-108 643 FQTRAGCLIGAE 672 111 111 111 661 ECDIPIGAGICA	92	51-92	547		550	
94 S1-94 S59 FEPTULFUENDIA S70 96 S1-96 S71 DITDAVRDPGTL S82 97 S1-97 S77 RDPOTLEILDIT S88 98 S1-98 S63 EILDITPCSFGG S94 99 S1-99 S89 PCSFGVSVITP 600 100 S1-100 S95 VSVITPGTNTSN 600 101 S1-101 601 GTNSNQAVLY 612 102 S1-102 607 QAVUYOCTEVPVAI 624 103 S1-103 613 QDVNCTEVPVAI 630 105 S1-104 619 EVPVAIHAQLT 630 106 S1-106 631 PTWRYSTGSNV 642 107 S1-107 637 STGSNVCOTRAG 654 108 S1-108 643 FGTRAGCLGAGE 654 109 S1-109 649 CLIGAEHVNNSY 660 111 S1-111 661 ECDIPIGAGICA 672	93	31-93	555		504	
95 S1-95 S65 FGRDIADTIDAY S76 96 S1-96 S71 DTDAVRDPOTL S82 97 S1-97 S77 RDPQTLEILDIT S88 98 S1-98 S83 EILDITPCSFGG S94 99 S1-99 S89 PCSFGGVSVITP 606 101 S1-101 601 GTNTSNQVAVLY 612 102 S1-102 607 QVAVLYQDVNCT 618 103 S1-103 613 QDVNCTEVPVAL 624 106 S1-105 625 HADQLTPTWRVY 630 107 S1-107 637 STGRNPGTRAG 648 Insoluble 108 S1-108 643 FOTRAGCIGA 672 110 S1-110 655 HVNNSYECDIPI 660 111 S1-111 667 GAGICASYOTOT 678 1113 S1-113 673 SYQTOTNSPRA 684 114 S1-114 679 NSPRARAGGGS 685	94	S1-94	559	FLPFQQFGRDIA	570	
96 S1-96 S71 DTTDAVROPCTL S82 97 S1-97 S77 RDPOTLEILDIT S88 98 S1-98 S83 PELDTPCSFGG S94 99 S1-99 S89 PCSEGGVSVITP 600 100 S1-100 695 VSVITPGTNTSN 600 101 S1-101 601 GTNTSNQVAVLY 612 102 S1-102 607 QVAVLYQDVNCT 618 103 S1-103 613 QDVNCTEVPVAI 624 105 S1-105 625 HADQLTTVNEVY 630 106 S1-106 631 PTWRVSTGSNV 642 107 S1-109 649 CLICAEHVNNSY 660 110 S1-110 665 HVNNSYECDIPI 666 111 S1-111 661 ECOIPIGAGICA 672 113 S1-113 673 SVATSUBJART 697 Insoluble 116 S2-2 692 IIAVTMSIGAEK 678	95	S1-95	565	FGRDIADTTDAV	576	
97 S1-97 S77 RDPOTLEILDIT 588 98 S1-98 583 EILDITPCSFGG 594 99 S1-99 589 PCSFGQVSVITP 600 100 S1-100 595 VSVITPGTNTSN 606 101 S1-101 601 GTNTSNQVAVLY 612 102 S1-102 607 QVAULYDDVNCT 618 103 S1-103 613 QDVNCTEVPVAI 624 104 S1-104 619 EVPVAIHADQLT 636 105 S1-105 625 HADQLTPTWRY 636 106 S1-108 643 FOTRAGCLICAE 648 108 S1-108 643 FOTRAGCLICAE 654 110 S1-110 661 ECDIPIGAGCA 672 111 S1-112 667 GAGICASYQITQT 676 113 S1-113 673 SVQITOTINSPRRA 684 114 S1-114 674 SVASOSIAVITM 697 Insolub	96	S1-96	571	DTTDAVRDPQTL	582	
98 S1-98 583 EILDIPCSFGG 594 99 S1-99 589 PCSFGGVSVITP 600 100 S1-100 595 VSVITPGTNTSN 600 101 S1-101 601 GTNTSNQAVLY 612 102 S1-102 607 QVAVLYQVNCT 618 103 S1-103 613 QDVNCTEVPVAI 624 105 S1-105 625 HADQLTFTWRVY 630 106 S1-106 631 PTWRVYSTGSNV 642 107 S1-107 637 STGSMVFOTRAG 648 Insoluble 108 S1-108 643 FQTRAGCIGA 672 110 S1-111 667 GAGICASYQTQT 678 111 S1-113 673 SYQTOTNSPRA 684 114 S1-114 679 Insoluble Failure for synthesis 115 S2-1 686 SVASQBIAVTM 697 Insoluble 116 S2-2 692 <td< td=""><td>97</td><td>S1-97</td><td>577</td><td>RDPQTLEILDIT</td><td>588</td><td></td></td<>	97	S1-97	577	RDPQTLEILDIT	588	
99 S1-90 589 PCSFGQVSVITP 600 100 S1-100 595 VSVITPGTNTSN 606 101 S1-101 601 GTNTSNQVAVLY 612 102 S1-102 607 QVAVLYQDVNCT 618 103 S1-103 613 QDVNCTEVPVAI 624 104 S1-104 619 EVPVAIHADQLT 636 105 S1-105 625 HADQLTPTWRY 636 106 S1-108 631 PTWRVYSTGSNV 642 108 S1-108 643 FOTRAGCLICAE 654 108 S1-109 649 CLICAEHVNNSY 660 110 S1-110 655 HVNNSYECDIPI 666 111 S1-111 661 ECDIPIAGEGS 685 1114 S1-114 673 SYQTOTT 678 1113 S1-113 673 SYQTOTT 678 1114 S1-114 674 SVASQSIAYTM 697 Insoluble	98	S1-98	583	EILDITPCSFGG	594	
100 S1-100 595 VSVTPCTVTSN 606 101 S1-101 601 GTNTSNQVAVLY 612 102 S1-102 607 QVAVLYQDVNCT 618 103 S1-103 613 QDVNCTEVPVAI 624 104 S1-105 625 HADQLTPTWRVY 630 105 S1-105 625 HADQLTPTWRVY 630 106 S1-106 631 PTWRVYSTGSNV 642 107 S1-109 649 CLICAEHVNNSY 660 110 S1-110 655 HVNNSYEODIPI 666 111 S1-111 667 GAGICASYQTQT 678 111 S1-113 673 SYQTOTNSPRRA 684 111 S1-114 679 NSPRRARGGGS 685 115 S2-1 686 SVASQSIAVTM 697 Insoluble 116 S2-2 692 IIAYTMSLGAEN 703 Failure for synthesis 117 S2-3 704	99	S1-99	589	PCSEGGVSVITP	600	
101 S1-101 601 GTNTSNQVAVLY 612 102 S1-102 607 QVAVLYDDVNCT 618 103 S1-103 613 QDVNCTEVPVAI 624 104 S1-106 625 HADQLTPVRVY 636 106 S1-106 631 PTWRVYSTGSNV 642 107 S1-108 643 FOTRAGCLIGAE 654 108 S1-108 643 FOTRAGCLIGAE 654 109 S1-108 643 FOTRAGCLIGAE 654 109 S1-110 665 HVNNSYECDIPI 666 111 S1-111 667 GAGICASYQTOT 678 113 S1-112 667 MAICAGEGGS 655 115 S2-1 686 SVASQSIAYTM 697 Insoluble 116 S2-2 692 IIAYTMSLGAEN 709 Insoluble 117 S2-3 698 SLGAENSVAYSN 709 Insoluble 117 S2-3 722 </td <td>100</td> <td>S1-100</td> <td>595</td> <td>VSVITPGTNTSN</td> <td>606</td> <td></td>	100	S1-100	595	VSVITPGTNTSN	606	
IDI S1+101 ODI GINISNUARLI OI2 102 S1+102 607 QUAVLYQUVNCT 618 103 S1+103 613 QDVNCTEVPVAI 624 104 S1+104 619 EVPVAIHADQLT 630 105 S1+106 631 PTWRYVSTGSNV 636 108 S1+108 643 FOTRAGCLICAE 654 109 S1+109 649 CLICAEHVNNSY 660 110 S1+111 661 ECDIPIGAGICA 672 111 S1+111 661 ECDIPIGAGICA 672 112 S1+112 667 GAGICASYQTQT 678 113 S1+113 673 SYQTQTNSPRRA 684 114 S1+114 679 NSPRARAGGGS 685 115 S2+1 686 SVASQSIIAYTM 697 Insoluble 116 S2+2 692 IIAYTMSLGAEN 703 Failure for synthesis 117 S2-3 698	100	S1-100 S1 101	601		612	
102 S1-102 607 QVACLYDVVL1 618 103 S1-103 613 QDVNCTEVPVAI 624 104 S1-104 619 EVPVAIHADQLT 630 105 S1-105 625 HADQLTPTWRVY 636 106 S1-107 637 STGSNVFQTRAG 648 Insoluble 108 S1-108 643 FOTRACLIGAE 654 109 S1-108 643 FOTRACLIGAE 654 100 S1-110 665 HVNNSVECDIPI 666 111 S1-111 667 GAGICASYOTOT 678 113 S1-112 667 GAGICASYOTOT 678 114 S1-113 673 SVOTOTNSPRRA 684 114 S1-114 679 NSPRRARGGGS 685 115 S2-1 686 SVASQSIAYTM 697 Insoluble 116 S2-2 692 IIAYTMSLGAEN 709 Insoluble 117 S2-3 698<	101	51-101	001	GINISNQVAVLI	012	
103 S1-103 613 QDVNC1EVPVAI 624 104 S1-104 619 EVPVAIHADQLT 630 105 S1-105 625 HADQLTPTWRVY 636 106 S1-106 631 PTWRYVSTGSNV 642 107 S1-108 643 FOTRAGCLIGAE 654 108 S1-108 643 FOTRAGCLIGAE 654 109 S1-109 649 CLIGAEHVINNSY 660 110 S1-110 655 HVNNSYECDIPI 666 111 S1-111 661 ECDIPIGAGICA 672 1112 S1-112 667 GAGICASYQTOT 678 1113 S1-113 673 SYQTQTNSPRRA 684 1115 S2-1 686 SVASQSIIAYTM 697 Insoluble 1116 S2-2 692 IIAYTMSLGAEN 703 Failure for synthesis 1117 S2-3 698 SLGAENSVAYSN 709 133 121 S2-7 722 VTELIPVSMTK 733 120 S2-6 710 NSIAIPTN	102	S1-102	607	QVAVLYQDVNCT	618	
104 S1-104 619 EVPVAIHADQLT 630 105 S1-105 625 HADQLTPWRVY 636 106 S1-106 631 PTWRVYSTOSNV 642 107 S1-107 637 STGSNVFQTRAG 648 Insoluble 108 S1-108 643 FOTRAGCLIGAE 654 109 S1-109 649 CLICAEHVINSY 660 111 S1-111 661 ECDIPIGAGICA 672 112 S1-113 673 SYQTQTUT 678 113 S1-114 679 NSPRARGGGGS 685 115 S2-1 666 SVASQSILAYTM 697 Insoluble 116 S2-2 692 ILAYTMSLGAEN 703 Failure for synthesis 117 S2-3 698 SLGAENSVAYSN 709 Insoluble 118 S2-4 704 SVAYSNSNIAIP 715 119 22-6 716 TYTEIVYSMTK 733 122 S2-6	103	S1-103	613	QDVNCTEVPVAI	624	
105 S1-105 625 HADQLTPTWRVY 636 106 S1-106 631 PTWRVYSTGSNV 642 107 S1-107 637 STGSNVFQTRAG 648 Insoluble 108 S1-108 643 FQTRAGCLIGAE 654 109 S1-109 649 CLIGAEHNNNSY 660 111 S1-110 655 HVNNSYECDIPI 666 111 S1-111 661 ECDIPIGAGICA 672 112 S1-113 673 SYQTQTNSPRRA 684 113 S1-113 673 SYQTQTNSPRRA 684 114 S2-1 686 SVASQSIIAYTM 697 Insoluble 115 S2-1 686 SVASQSIIAYTM 697 Insoluble 116 S2-2 692 IIAYTMSLGAEN 709 Tial S2-3 710 NSIAPRATKSVDCT 739 117 S2-3 698 SLGAENSVAYSN 709 Tialure for synthesis 121 S2-7 7	104	S1-104	619	EVPVAIHADQLT	630	
106 S1-106 631 PTWRVYSTGSNV 642 107 S1-107 637 STGSNVFQTRAG 648 Insoluble 108 S1-108 643 FQTRAGCLIGAE 654 109 S1-109 649 CLIGAEHVINNSY 660 110 S1-110 655 HVNNSYECDIPI 666 111 S1-111 661 ECDIPIGAGICA 672 112 S1-113 673 SYQTQTTNSPRRA 684 114 S1-114 679 NSPRARGGGGS 685 115 S2-1 686 SVASQSIIAYTM 697 Insoluble 116 S2-2 692 IIAYTMSLGAEN 703 Failure for synthesis 117 S2-3 698 SLGAENSVAYSN 709 118 S2-4 704 SVAYSNSIAIP 715 119 S2-5 710 NSIAIPTNFTIS 721 120 S2-6 716 TYTEIVSVDCT 739 122 S2-8 728 PVSMTKTSVDCT<	105	S1-105	625	HADQLTPTWRVY	636	
107 S1-107 637 STGSNVFOTRAG 648 Insoluble 108 S1-108 643 FQTRAGCLIGAE 654 109 S1-109 649 CLIGAEHVNNSY 660 110 S1-110 655 HVNNSYECDIPI 666 111 S1-111 661 ECDIPIGAGICA 672 112 S1-112 667 GAGICASYQTQT 678 113 S1-113 673 SYQTQTINSPRRA 684 114 S1-114 679 NSPRRAGGGS 685 115 S2-1 686 SVASQSIIAYTM 697 Insoluble 116 S2-2 692 IIAYTMSLGAEN 703 Failure for synthesis 117 S2-3 698 SLGAENSVAYSN 709 113 S2-5 710 NSIAPTNETIS 721 120 S2-6 716 TNFTISVTTEIL 727 Failure for synthesis 121 S2-10 740 SVACOSTMICA 739 122 <td< td=""><td>106</td><td>S1-106</td><td>631</td><td>PTWRVYSTGSNV</td><td>642</td><td></td></td<>	106	S1-106	631	PTWRVYSTGSNV	642	
108 S1-108 643 FOTRAGCLIGAE 654 109 S1-109 649 CLIGAEHVINSY 660 110 S1-110 655 HVINNSYECDIPI 666 111 S1-111 661 ECDIPIGAGICA 672 112 S1-112 667 GAGICASYQTQT 678 113 S1-113 673 SYQTQTINSPRRA 684 114 S1-114 679 NSPRAAGGGGS 685 115 S2-1 686 SVASOSIIAYTM 697 Insoluble 116 S2-2 692 IIAYTMSLGAEN 703 Failure for synthesis 117 S2-3 698 SLGAENSVAYSN 709 118 S2-4 120 S2-6 716 TNFTISVTTEIL 727 Failure for synthesis 121 S2-7 722 VTTEILPVSMTK 733 122 S2-8 728 PVSMTKTSVDCT 739 123 S2-9 734 TSVDCTMYICGD 745 Failure for synthesis<	107	S1-107	637	STGSNVFQTRAG	648	Insoluble
100 S1-109 649 CLIGAEHVNNSY 660 110 S1-110 655 HVNNSYECDIPI 666 111 S1-111 661 ECDIPIGAGICA 672 112 S1-112 667 GAGICASYQTQT 678 113 S1-113 673 SYQTQTINSPRA 684 114 S1-114 679 NSPRRARGGGS 685 115 S2-1 686 SVASQSIIAYTM 697 Insoluble 116 S2-2 692 IIAYTMSLGAEN 703 Failure for synthesis 117 S2-3 698 SLGAENSVAYSN 709 118 S2-4 704 SVAYSINSIAP 715 119 S2-5 710 NSIAIPINFTIS 721 120 S2-6 716 TNFTISVDCT 739 122 S2-8 728 PVSMTKTSVDCT 739 123 S2-9 734 TSVDCTMYIC6D 745 Failure for synthesis 124 S2-11 746 STECSNLLLQYG	108	\$1-108	643	EOTRAGCUIGAE	654	
103 51103 053 CLUMNET (INTO) 053 110 S1-110 655 HVNNSYECDPI 666 111 S1-111 661 ECDIPIGAGICA 672 112 S1-113 673 SYQTQTNSPRRA 684 114 S1-114 679 NSPRARGGGS 685 115 S2-1 686 SVASQSIIA/TM 697 Insoluble 116 S2-2 692 IIA/TMSLGAEN 703 Failure for synthesis 117 S2-3 698 SLGAENSVAYSN 709 118 118 S2-4 704 SVAYSINNSIAIP 715 119 S2-5 710 NSIAPTNFTIS 721 120 S2-6 716 TNFTISVTTEIL 727 121 S2-7 722 VTTELPVSMTK 733 122 S2-8 728 PVSMTKTSVDCT 739 123 S2-9 734 TSVDCTMVICID 745 124 S2-11 746	100	S1_100	649		660	
110 S1-110 603 HVMNS (EC)(F) 600 111 S1-111 667 GAGICASYQTQT 678 112 S1-112 667 GAGICASYQTQT 678 113 S1-113 673 SYQTQTNSPRRA 684 114 S1-114 679 NSPRARGGGGS 685 115 S2-1 686 SVASQSIAYTM 697 Insoluble 116 S2-2 692 IIAYTMSLGAEN 703 Failure for synthesis 117 S2-3 698 SLGAENSVAYSN 709 118 120 S2-6 716 TNFTISVTTEIL 727 Failure for synthesis 121 S2-7 722 VTTEILPVSMTK 733 122 S2-8 728 PVSMTKTSVDCT 739 123 S2-9 734 TSVDCTMYICGD 745 Failure for synthesis 124 S2-11 746 STECNLLQYG 757 126 S2-12 752 LLLQYGSFCTQL 763 127 S2-13 758 SFCTQLNRALTG 769 Insoluble	100	S1-103 S1 110	655		666	
111 S1-111 001 ECDIPLAGICA 672 112 S1-1112 667 GGGICASYGTQT 678 113 S1-113 673 SYQTQTNSPRRA 684 114 S1-114 679 NSPRRARGGGS 685 115 S2-1 686 SVASQSIIAYTM 697 Insoluble 116 S2-2 692 IIAYTMSLGAEN 703 Failure for synthesis 117 S2-3 698 SLGAENSVAYSN 709	110	51-110	000		000	
112 S1-112 667 GAGICASYQ1Q1 678 113 S1-112 667 GAGICASYQ1Q1 678 114 S1-114 679 NSPRRARGGGGS 684 115 S2-1 686 SVASQSIIAYTM 697 Insoluble 116 S2-2 692 IIAYTMSLGAEN 703 Failure for synthesis 117 S2-3 698 SLGAENSVAYSN 709 118 S2-4 704 SVAYSINISIAIP 715 119 S2-5 710 NSIAPTNFTIS 721 120 S2-6 716 TNFTISVDTFIIS 721 121 S2-7 722 VTTEILPVSMTK 733 122 S2-8 722 VTTEILPVSMTK 733 123 S2-9 734 TSVDCTMYICGD 745 Failure for synthesis 124 S2-10 740 MYICGDSTECSN 751 126 S2-11 752 LLQYGSFCTQL 763 127 S2-13 758 SFCTQLNRALTG 769 Insoluble 133 132 S2-16 7	111	S1-111	661	ECDIPIGAGICA	672	
113 S1-113 673 SYQTQTNSPRRA 684 114 S1-114 679 NSPRARGGGS 685 115 S2-1 686 SVASQSIIAYTM 697 Insoluble 116 S2-2 692 IIAYTMSLGAEN 703 Failure for synthesis 117 S2-3 698 SLGAENSVAYSN 709 1 118 S2-4 704 SVAYSNNSIAIP 715 1 119 S2-5 710 NSIAIPTNFTIS 721 Failure for synthesis 121 S2-7 722 VTTEILPVSMTK 733 1 122 S2-8 728 PVSMTKTSVDCT 739 122 S2-4 728 PVSMTKTSVDCT 733 1 125 S2-11 746 STECSNLLQYG 751 126 S2-12 752 LLLQYGSFCTQL 763 1 1 1 127 S2-13 758 SFCTQLNRALTG 769 1 1 1 1 1 1 1 1 1 1 1 1 1 1	112	S1-112	667	GAGICASYQIQI	678	
114 S1-114 679 NSPRARGGGGS 685 115 S2-1 686 SVASQSIIAYTM 697 Insoluble 116 S2-2 692 IIAYTMSLGAEN 703 Failure for synthesis 117 S2-3 698 SLGAENSVAYSN 709 118 S2-4 704 SVAYSNNSIAIP 715 119 S2-5 710 NSIAIPTNFTIS 721 120 S2-6 716 TNFTISVTTEIL 727 Failure for synthesis 121 S2-7 722 VITEILPVSMTK 733 122 S2-8 728 PVSMTKTSVDCT 739 123 S2-9 734 TSVDCTMYICGD 745 Failure for synthesis 124 S2-10 740 MYICGDSTECSN 751 75 126 S2-12 752 LLQYGSFCTQL 763 1soluble 127 S2-13 758 SFCTQLNRALTG 769 Insoluble 128 S2-14 764 NRALTGIAVEQD 787 130 S2-15 770 IAVEQDKNTQEV<	113	S1-113	673	SYQTQTNSPRRA	684	
115 S2-1 686 SVASQSIIAYTM 697 Insoluble 116 S2-2 692 IIAYTMSLGAEN 703 Failure for synthesis 117 S2-3 698 SLGAENSVAYSN 709 118 S2-4 704 SVAYSNNSIAIP 715 119 S2-5 710 NSIAIPTNFTIS 721 120 S2-6 716 TNFTISVTTEIL 727 Failure for synthesis 121 S2-7 722 VTTEILPVSMTK 733 122 S2-8 728 PVSMTKTSVDCT 739 123 S2-9 734 TSVDCTMYICGD 745 Failure for synthesis 124 S2-10 740 MYICGDSTECSN 751 125 S2-11 746 STECSNLLQYG 757 126 S2-12 752 LLLQYGSFCTQL 763 127 S2-13 758 SFCTQLNRALTG 769 Insoluble 128 S2-14 764 NRALTGIAVEQD 775 131	114	S1-114	679	NSPRRARGGGGS	685	
116 S2-2 692 IIAYTMSLGAEN 703 Failure for synthesis 117 S2-3 698 SLGAENSVAYSN 709 118 S2-4 704 SVAYSNNSIAIP 715 119 S2-5 710 NSIAIPTNFTIS 721 120 S2-6 716 TNFTISVTEIL 727 Failure for synthesis 121 S2-7 722 VTTEILPVSMTK 733 733 122 S2-8 728 PVSMTKTSVDCT 739 123 S2-9 734 TSVDCTMYICGD 745 Failure for synthesis 124 S2-10 740 MYICGDSTECSN 751 125 S2-11 746 STECSNLLQYG 763 127 S2-13 758 SFCTQLNRALTG 769 Insoluble 128 S2-14 764 NRALTGAVEQD 775 129 S2-15 770 IAVEQKNTQEV 781 130 S2-16 776 KNTQEVFAQVKQ 787	115	S2-1	686	SVASQSIIAYTM	697	Insoluble
117 S2-3 698 SLGAENSVAYSN 709 118 S2-4 704 SVAYSNNSIAIP 715 119 S2-5 710 NSIAIPTNFTIS 721 120 S2-6 716 TNFTISVTTEIL 727 Failure for synthesis 121 S2-7 722 VTTEILPVSMTK 733 122 S2-8 728 PVSMTKTSVDCT 739 133 S2-9 734 TSVDCTMYICGD 745 Failure for synthesis 124 S2-10 740 MYICGDSTECSN 751 125 S2-11 746 STECSNLLLQYG 757 126 S2-12 752 LLLQYGSFCTQL 763 127 S2-13 758 SFCTQLNRALTG 769 Insoluble 128 S2-14 764 NRALTGIAVEQD 775 129 S2-15 770 IAVEQDKNTGEV 781 130 S2-17 782 FAQVKQIYKTPP 793 131 S2-17	116	S2-2	692	IIAYTMSLGAEN	703	Failure for synthesis
111 52-0 560 CSURTING 750 118 S2-4 704 SVAYSINISIAIP 715 119 S2-5 710 NSIAIPTNFTIS 721 120 S2-6 716 TNFTISVTTEIL 727 Failure for synthesis 121 S2-7 722 VTTEILPVSMTK 733 122 S2-8 728 PVSMTKTSVDCT 739 123 S2-9 734 TSVDCTMVICGD 745 Failure for synthesis 124 S2-10 740 MYICGDSTECSN 751 126 S2-11 746 STECSNLLLQYG 757 126 S2-12 752 LLLQYGSFCTQL 763 152 153 160 170 IAVEODKNTQEV 781 130 S2-16 776 KNTQEVFAQVKQ 787 131 S2-17 782 FAQVKQIYKTPP 793 131 S2-17 782 FAQVKQIYKTPP 793 132 S2-18 788 IYKTPPIKDFGG 799	117	S2-3	698	SI GAENSVAYSN	709	,
110 32-4 104 3VATSINIOLITY 113 119 S2-5 710 NSIAIPTNFTIS 721 120 S2-6 716 TNFTISVTTEIL 727 Failure for synthesis 121 S2-7 722 VTTEILPVSMTK 733 122 S2-8 728 PVSMTKTSVDCT 739 123 S2-9 734 TSVDCTMYICGD 745 Failure for synthesis 124 S2-10 740 MYICGDSTECSN 751 751 125 S2-11 746 STECSNLLLQYG 757 126 S2-12 752 LLLQYGSFCTQL 763 127 S2-13 758 SFCTQLNRALTG 769 Insoluble 128 S2-14 764 NRALTGIAVEQD 775 130 S2-15 770 IAVEQDK/TQEV 781 130 S2-16 776 KNTQEVFAQVKQ 787 131 S2-17 782 FAQVKQIYKTPP 793 132 S2-18 788 IYKTPPIKDFGG 799 133 S2-21 806 LPDPSKPSKRSF <	110	S2 /	704	SVAVSNINSIAID	700	
119 32-3 710 INSIAIPTINETIS 721 120 S2-6 716 TNFTISVTTEIL 727 Failure for synthesis 121 S2-7 722 VTTEILPVSMTK 733 122 S2-8 728 PVSMTKTSVDCT 739 123 S2-9 734 TSVDCTMYICGD 745 Failure for synthesis 124 S2-10 740 MYICGDSTECSN 751 125 S2-11 746 STECSNLLLQYG 757 126 S2-12 752 LLLQYGSFCTQL 763 127 S2-13 758 SFCTQLNRALTG 769 Insoluble 128 S2-14 764 NRALTGIAVEQD 775 129 S2-15 770 IAVEQDKNTQEV 781 130 S2-16 776 KNTQEVFAQVKQ 787 131 S2-17 782 FAQVKQIYKTPP 793 132 S2-18 788 IYKTPPIKDFGG 799 133 S2-19 794 IKDFGGFNFSQI 805 134 S2-20 800<	110	02-4	704	NEIAIDTNETIE	713	
120 S2-6 716 INF HSVT HELL 727 Failure for synthesis 121 S2-7 722 VTTEILPVSMTK 733 122 S2-8 728 PVSMTKTSVDCT 739 123 S2-9 734 TSVDCTMYICGD 745 Failure for synthesis 124 S2-10 740 MYICGDSTECSN 751 125 S2-11 746 STECSNLLQYG 757 126 S2-12 752 LLLQYGSFCTQL 763 127 S2-13 758 SFCTQLNRALTG 769 Insoluble 128 S2-14 764 NRALTGIAVEQD 775 129 S2-15 770 IAVEQDKNTQEV 781 130 S2-16 776 KNTQEVFAQVKQ 787 131 S2-17 782 FAQVKQIYKTPP 793 132 S2-18 788 IYKTPPIKDFGG 799 133 S2-19 794 IKDFGGFNSQI 805 134 S2-20 800 FNFSQILPDPSK 817 135 S2-21 806 <td>119</td> <td>52-5</td> <td>710</td> <td>INSTAIL THE THE</td> <td>721</td> <td>Entire francesta and</td>	119	52-5	710	INSTAIL THE THE	721	Entire francesta and
121 S2-7 722 VTTEILPVRIK 733 122 S2-8 728 PVSMTKTSVDCT 739 123 S2-9 734 TSVDCTMVICGD 745 Failure for synthesis 124 S2-10 740 MYICGDSTECSN 751 125 S2-11 746 STECSNLLLQYG 757 126 S2-12 752 LLLQYGSFCTQL 763 127 S2-13 758 SFCTQLNRALTG 769 Insoluble 128 S2-14 764 NRALTGIAVEQD 775 129 S2-15 770 IAVEQDKNTQEV 781 130 S2-16 776 KNTQEVFAQVKQ 787 131 S2-17 782 FAQVKQVKQ 787 131 S2-17 782 FAQVKQVKQ 787 133 S2-19 794 IKDFGGFNFSQI 805 133 S2-19 794 IKDFGGFNFSQI 805 141 135 S2-22 812 PSKRSFIEDLLF 823 136 S2-22 812 PSKRSFIEDLLF 823 137 S2-23 <td< td=""><td>120</td><td>S2-6</td><td>/16</td><td>INFIISVITEIL</td><td>121</td><td>Failure for synthesis</td></td<>	120	S2-6	/16	INFIISVITEIL	121	Failure for synthesis
122 S2-8 728 PVSMTKTSVDCT 739 123 S2-9 734 TSVDCTMYICGD 745 Failure for synthesis 124 S2-10 740 MYICGDSTECSN 751 125 S2-11 746 STECSNLLLQYG 757 126 S2-12 752 LLLQYGSFCTQL 763 127 S2-13 758 SFCTQLNRALTG 769 Insoluble 128 S2-14 764 NRALTGIAVEQD 775 129 S2-15 770 IAVEQDKNTQEV 781 130 S2-16 776 KNTQEVFAQVKQ 787 131 S2-17 782 FAQVKQIYKTPP 793 132 S2-18 788 IYKTPPIKDFGG 799 133 S2-19 794 IKDFGGFNFSQI 805 134 S2-20 800 FNFSQILPDPSK 811 135 S2-21 806 LPDPSKPSKRSF 817 136 S2-22 812 PSKRSFIEDLLF 823 137 S2-23 818 IEDLLFNKVTLA	121	S2-7	722	VTTEILPVSMTK	733	
123 S2-9 734 TSVDCTMYICGD 745 Failure for synthesis 124 S2-10 740 MYICGDSTECSN 751 125 S2-11 746 STECSNLLLQYG 757 126 S2-12 752 LLLQYGSFCTQL 763 127 S2-13 758 SFCQLNRALTG 769 Insoluble 128 S2-14 764 NRALTGIAVEQD 775 129 S2-15 770 IAVEQDKNTQEV 781 130 S2-16 776 KNTQEVFAQVKQ 787 131 S2-17 782 FAQVKQIYKTPP 793 132 S2-18 788 IYKTPPIKDFGG 799 133 S2-19 794 IKDFGGFNFSQI 805 134 S2-20 800 FNFSQILPDPSK 811 135 S2-21 806 LPDPSKPSKRSF 817 136 S2-22 812 PSKRSFIEDLLF 823 137 S2-23 818 IEDLLFNKVTLA 829 138 S2-24 824 NKVTLADAGFIK	122	S2-8	728	PVSMTKTSVDCT	739	
124 S2-10 740 MYICGDSTECSN 751 125 S2-11 746 STECSNLLQYG 757 126 S2-12 752 LLLQYGSFCTQL 763 127 S2-13 758 SFCTQLNRALTG 769 Insoluble 128 S2-14 764 NRALTGIAVEQD 775 129 S2-15 770 IAVEQDKNTQEV 781 130 S2-16 776 KNTQEVFAQVKQ 787 131 S2-17 782 FAQVKQIYKTPP 793 132 S2-18 788 IYKTPPIKDFGG 799 133 S2-19 794 IKDFGGFNFSQI 805 134 S2-20 800 FNFSQILPDPSK 811 135 S2-21 806 LPDPSKPSKRSF 817 136 S2-22 812 PSKRSFIEDLLF 823 137 S2-23 818 IEDLFNKVTLA 829 138 S2-24 824 NKVTLADAGFIK 835 Failure for synthesis 139 S2-25 830 DAGFIKQYGDCL	123	S2-9	734	TSVDCTMYICGD	745	Failure for synthesis
125 S2-11 746 STECSNLLLQYG 757 126 S2-12 752 LLLQYGSFCTQL 763 127 S2-13 758 SFCTQLNRALTG 769 Insoluble 128 S2-14 764 NRALTGIAVEQD 775 129 S2-15 770 IAVEQDKNTQEV 781 130 S2-16 776 KNTQEVFAQVKQ 787 131 S2-17 782 FAQVKQIYKTPP 793 132 S2-18 788 IYKTPPIKDFGG 799 133 S2-19 794 IKDFGGFNFSQI 805 134 S2-20 800 FNFSQILPDPSK 811 135 S2-21 806 LPDPSKPSKRSF 817 136 S2-22 812 PSKRSFIEDLIF 823 137 S2-23 818 IEDLLFNKVTLA 829 138 S2-24 824 NKVTLADAGFIK 835 Failure for synthesis 139 S2-25 830 DAGFIKQYGDCL 841 140 S2-26 836 QYGDCLGDIAAR	124	S2-10	740	MYICGDSTECSN	751	
126 S2-12 752 LLLQYGSFCTQL 763 127 S2-13 758 SFCTQLNRALTG 769 Insoluble 128 S2-14 764 NRALTGIAVEQD 775 129 S2-15 770 IAVEQDKNTQEV 781 130 S2-16 776 KNTQEVFAQVKQ 787 131 S2-17 782 FAQVKQIYKTPP 793 132 S2-18 788 IYKTPPIKDFGG 799 133 S2-19 794 IKDFGGFNFSQI 805 134 S2-20 800 FNFSQILPDPSK 811 135 S2-21 806 LPDPSKPSKRSF 817 136 S2-22 812 PSKRSFIEDLLF 823 137 S2-23 818 IEDLLFNKVTLA 829 138 S2-24 824 NKVTLADAGFIK 835 Failure for synthesis 139 S2-25 830 DAGFIKQYGDCL 841 140 S2-26 836 QYGDCLGDIAAR 847 141 S2-27 842 GDIAARDLICAQ	125	S2-11	746	STECSNLLLQYG	757	
127 S2-13 758 SFCTQLNRALTG 769 Insoluble 128 S2-14 764 NRALTGIAVEQD 775 129 S2-15 770 IAVEQDKNTQEV 781 130 S2-16 776 KNTQEVFAQVKQ 787 131 S2-17 782 FAQVKQIYKTPP 793 132 S2-18 788 IYKTPPIKDFGG 799 133 S2-19 794 IKDFGGFNFSQI 805 134 S2-20 800 FNFSQILPDPSK 811 135 S2-21 806 LPDPSKPSKRSF 817 136 S2-22 812 PSKRSFIEDLLF 823 137 S2-23 818 IEDLLFNKVTLA 829 138 S2-24 824 NKVTLADAGFIK 835 Failure for synthesis 139 S2-25 830 DAGFIKQYGDCL 841 140 S2-26 836 QYGDCLGDIAAR 847 141 S2-27 842 GDIAARDLICAQ 853 142 S2-28 848 DLICAQKFNGLT	126	S2-12	752	I I I QYGSECTOI	763	
121 01 100 01 100 100 100 100 128 S2-14 764 NRALTGIAVEQD 775 129 S2-15 770 IAVEQDKNTQEV 781 130 S2-16 776 KNTQEVFAQVKQ 787 131 S2-17 782 FAQVKQIYKTPP 793 132 S2-18 788 IYKTPPIKDFGG 799 133 S2-19 794 IKDFGGFNFSQI 805 134 S2-20 800 FNFSQILPDPSK 811 135 S2-21 806 LPDPSKPSKRSF 817 136 S2-22 812 PSKRSFIEDLLF 823 137 S2-23 818 IEDLLFNKVTLA 829 138 S2-24 824 NKVTLADAGFIK 835 Failure for synthesis 139 S2-25 830 DAGFIKQYGDCL 841 140 S2-26 836 QYGDCLGDIAAR 847 141 S2-27 842 GDIAARDLICAQ 853 142 S2-28 848	127	S2-13	758	SECTOLNBALTG	769	Insoluble
120 52-14 104 INALTONALQD 173 129 52-15 770 IAVEQDKNTQEV 781 130 52-16 776 KNTQEVFAQVKQ 787 131 52-17 782 FAQVKQIYKTPP 793 132 52-18 788 IYKTPPIKDFGG 799 133 52-19 794 IKDFGGFNFSQI 805 134 52-20 800 FNFSQILPDPSK 811 135 52-21 806 LPDPSKPSKRSF 817 136 52-22 812 PSKRSFIEDLLF 823 137 52-23 818 IEDLLFNKVTLA 829 138 52-24 824 NKVTLADAGFIK 835 Failure for synthesis 139 52-25 830 DAGFIKQYGDCL 841 140 52-26 836 QYGDCLGDIAAR 847 141 52-27 842 GDIAARDLICAQ 853 142 52-28 848 DLICAQKFNGLT 859 143 52-29 854 KFNGLTVLPPLL 865 <td>128</td> <td>S2-14</td> <td>764</td> <td></td> <td>775</td> <td>moorabic</td>	128	S2-14	764		775	moorabic
129 S2-15 770 IAVEQUKNIQEV 781 130 S2-16 776 KNTQEVFAQVKQ 787 131 S2-17 782 FAQVKQIYKTPP 793 132 S2-18 788 IYKTPPIKDFGG 799 133 S2-19 794 IKDFGGFNFSQI 805 134 S2-20 800 FNFSQILPDPSK 811 135 S2-21 806 LPDPSKPSKRSF 817 136 S2-22 812 PSKRSFIEDLLF 823 137 S2-23 818 IEDLLFNKVTLA 829 138 S2-24 824 NKVTLADAGFIK 835 Failure for synthesis 139 S2-25 830 DAGFIKQYGDCL 841 140 S2-26 836 QYGDCLGDIAAR 847 141 S2-27 842 GDIAARDLICAQ 853 142 S2-28 848 DLICAQKFNGLT 859 143 S2-29 854 KFNGLTVLPPLL 865 144 S2-30 860 VLPPLLTDEMIA 871 <td>120</td> <td>00.45</td> <td>704</td> <td></td> <td>773</td> <td></td>	120	00.45	704		773	
130 S2-16 /76 KNTQEVFAQVKQ 787 131 S2-17 782 FAQVKQIYKTPP 793 132 S2-18 788 IYKTPPIKDFGG 799 133 S2-19 794 IKDFGGFNFSQI 805 134 S2-20 800 FNFSQILPDPSK 811 135 S2-21 806 LPDPSKPSKRSF 817 136 S2-22 812 PSKRSFIEDLLF 823 137 S2-23 818 IEDLLFNKVTLA 829 138 S2-24 824 NKVTLADAGFIK 835 Failure for synthesis 139 S2-25 830 DAGFIKQYGDCL 841 140 S2-27 842 GDIAARDLICAQ 853 141 S2-27 842 GDIAARDLICAQ 853 142 S2-28 848 DLICAQKFNGLT 859 143 S2-29 854 KFNGLTVLPPLL 865 144 S2-30 860 VLPPLLTDEMIA 871 145 S2-31 866 TDEMIAQYTSAL 877 <td>129</td> <td>52-15</td> <td>770</td> <td>IAVEQUENTQEV</td> <td>701</td> <td></td>	129	52-15	770	IAVEQUENTQEV	701	
131 S2-17 782 FAQVKQIYKTPP 793 132 S2-18 788 IYKTPPIKDFGG 799 133 S2-19 794 IKDFGGFNFSQI 805 134 S2-20 800 FNFSQILPDPSK 811 135 S2-21 806 LPDPSKPSKRSF 817 136 S2-22 812 PSKRSFIEDLLF 823 137 S2-23 818 IEDLLFNKVTLA 829 138 S2-24 824 NKVTLADAGFIK 835 Failure for synthesis 139 S2-25 830 DAGFIKQYGDCL 841 140 S2-26 836 QYGDCLGDIAAR 847 141 S2-27 842 GDIAARDLICAQ 853 142 S2-28 848 DLICAQKFNGLT 859 143 S2-29 854 KFNGLTVLPPLL 865 144 S2-30 860 VLPPLLTDEMIA 871 145 S2-31 866 TDEMIAQYTSAL 877	130	S2-16	//6	KNIQEVFAQVKQ	/8/	
132 S2-18 788 IYKTPPIKDFGG 799 133 S2-19 794 IKDFGGFNFSQI 805 134 S2-20 800 FNFSQILPDPSK 811 135 S2-21 806 LPDPSKPSKRSF 817 136 S2-22 812 PSKRSFIEDLLF 823 137 S2-23 818 IEDLLFNKVTLA 829 138 S2-24 824 NKVTLADAGFIK 835 Failure for synthesis 139 S2-25 830 DAGFIKQYGDCL 841 140 S2-26 836 QYGDCLGDIAAR 847 141 S2-27 842 GDIAARDLICAQ 853 142 S2-28 848 DLICAQKFNGLT 859 143 S2-29 854 KFNGLTVLPPLL 865 144 S2-30 860 VLPPLLTDEMIA 871 145 S2-31 866 TDEMIAQYTSAL 877	131	S2-17	782	FAQVKQIYKTPP	793	
133 S2-19 794 IKDFGGFNFSQI 805 134 S2-20 800 FNFSQILPDPSK 811 135 S2-21 806 LPDPSKPSKRSF 817 136 S2-22 812 PSKRSFIEDLLF 823 137 S2-23 818 IEDLLFNKVTLA 829 138 S2-24 824 NKVTLADAGFIK 835 Failure for synthesis 139 S2-25 830 DAGFIKQYGDCL 841 140 S2-26 836 QYGDCLGDIAAR 847 141 S2-27 842 GDIAARDLICAQ 853 142 S2-28 848 DLICAQKFNGLT 859 143 S2-29 854 KFNGLTVLPPLL 865 144 S2-30 860 VLPPLLTDEMIA 871 145 S2-31 866 TDEMIAQYTSAL 877	132	S2-18	788	IYKTPPIKDFGG	799	
134 S2-20 800 FNFSQILPDPSK 811 135 S2-21 806 LPDPSKPSKRSF 817 136 S2-22 812 PSKRSFIEDLLF 823 137 S2-23 818 IEDLLFNKVTLA 829 138 S2-24 824 NKVTLADAGFIK 835 Failure for synthesis 139 S2-25 830 DAGFIKQYGDCL 841 140 S2-26 836 QYGDCLGDIAAR 847 141 S2-27 842 GDIAARDLICAQ 853 142 S2-28 848 DLICAQKFNGLT 859 143 S2-29 854 KFNGLTVLPPLL 865 144 S2-30 860 VLPPLLTDEMIA 871 145 S2-31 866 TDEMIAQYTSAL 877	133	S2-19	794	IKDFGGFNFSQI	805	
135 S2-21 806 LPDPSKPSKRSF 817 136 S2-22 812 PSKRSFIEDLLF 823 137 S2-23 818 IEDLLFNKVTLA 829 138 S2-24 824 NKVTLADAGFIK 835 Failure for synthesis 139 S2-25 830 DAGFIKQYGDCL 841 140 S2-26 836 QYGDCLGDIAAR 847 141 S2-27 842 GDIAARDLICAQ 853 142 S2-28 848 DLICAQKFNGLT 859 143 S2-29 854 KFNGLTVLPPLL 865 144 S2-30 860 VLPPLLTDEMIA 871 145 S2-31 866 TDEMIAQYTSAL 877	134	S2-20	800	FNFSQILPDPSK	811	
136 S2-22 812 PSKRSFIEDLLF 823 137 S2-23 818 IEDLLFNKVTLA 829 138 S2-24 824 NKVTLADAGFIK 835 Failure for synthesis 139 S2-25 830 DAGFIKQYGDCL 841 140 S2-26 836 QYGDCLGDIAAR 847 141 S2-27 842 GDIAARDLICAQ 853 142 S2-28 848 DLICAQKFNGLT 859 143 S2-29 854 KFNGLTVLPPLL 865 144 S2-30 860 VLPPLLTDEMIA 871 145 S2-31 866 TDEMIAQYTSAL 877	135	S2-21	806	LPDPSKPSKRSF	817	
137 S2-23 818 IEDLLFNKVTLA 829 138 S2-24 824 NKVTLADAGFIK 835 Failure for synthesis 139 S2-25 830 DAGFIKQYGDCL 841 140 S2-26 836 QYGDCLGDIAAR 847 141 S2-27 842 GDIAARDLICAQ 853 142 S2-28 848 DLICAQKFNGLT 859 143 S2-29 854 KFNGLTVLPPLL 865 144 S2-30 860 VLPPLLTDEMIA 871 145 S2-31 866 TDEMIAQYTSAL 877	136	S2-22	812	PSKRSFIFDLLF	823	
138 S2-24 824 NKVTLADAGFIK 835 Failure for synthesis 139 S2-25 830 DAGFIKQYGDCL 841 140 S2-26 836 QYGDCLGDIAAR 847 141 S2-27 842 GDIAARDLICAQ 853 142 S2-28 848 DLICAQKFNGLT 859 143 S2-29 854 KFNGLTVLPPLL 865 144 S2-30 860 VLPPLLTDEMIA 871 145 S2-31 866 TDEMIAQYTSAL 877	137	\$2_22	R1R		820	
130 52-24 624 NKVTLADAGTIK 835 Failure for synthesis 139 \$2-25 830 DAGFIKQYGDCL 841 140 \$2-26 836 QYGDCLGDIAAR 847 141 \$2-27 842 GDIAARDLICAQ 853 142 \$2-28 848 DLICAQKFNGLT 859 143 \$2-29 854 KFNGLTVLPPLL 865 144 \$2-30 860 VLPPLLTDEMIA 871 145 \$2-31 866 TDEMIAQYTSAL 877	107	62.20	010		023	Egilura for outbasis
139 52-25 830 DAGFIKQYGDCL 841 140 S2-26 836 QYGDCLGDIAAR 847 141 S2-27 842 GDIAARDLICAQ 853 142 S2-28 848 DLICAQKFNGLT 859 143 S2-29 854 KFNGLTVLPPLL 865 144 S2-30 860 VLPPLLTDEMIA 871 145 S2-31 866 TDEMIAQYTSAL 877	130	52-24	024		030	Failure for synthesis
140 S2-26 836 QYGDCLGDIAAR 847 141 S2-27 842 GDIAARDLICAQ 853 142 S2-28 848 DLICAQKFNGLT 859 143 S2-29 854 KFNGLTVLPPLL 865 144 S2-30 860 VLPPLLTDEMIA 871 145 S2-31 866 TDEMIAQYTSAL 877	139	52-25	830	DAGFIKQYGDCL	841	
141 S2-27 842 GDIAARDLICAQ 853 142 S2-28 848 DLICAQKFNGLT 859 143 S2-29 854 KFNGLTVLPPLL 865 144 S2-30 860 VLPPLLTDEMIA 871 145 S2-31 866 TDEMIAQYTSAL 877	140	S2-26	836	QYGDCLGDIAAR	847	
142 S2-28 848 DLICAQKFNGLT 859 143 S2-29 854 KFNGLTVLPPLL 865 144 S2-30 860 VLPPLLTDEMIA 871 145 S2-31 866 TDEMIAQYTSAL 877	141	S2-27	842	GDIAARDLICAQ	853	
143 S2-29 854 KFNGLTVLPPLL 865 144 S2-30 860 VLPPLLTDEMIA 871 145 S2-31 866 TDEMIAQYTSAL 877	142	S2-28	848	DLICAQKFNGLT	859	
144 S2-30 860 VLPPLLTDEMIA 871 145 S2-31 866 TDEMIAQYTSAL 877	143	S2-29	854	KFNGLTVLPPLL	865	
145 S2-31 866 TDEMIAQYTSAL 877	144	S2-30	860	VLPPLLTDEMIA	871	
	145	S2-31	866	TDEMIAQYTSAL	877	

-

	00.00				
146	S2-32	872	QYTSALLAGTIT	883	
147	52-33	878	LAGTITSGW/TEG	880	
147	02-00	010	EAGINGOWING	000	
148	S2-34	884	SGWTFGAGAALQ	895	
1/0	\$2_35	800		001	
140	02-00	000	AOAALQII I AMQ	501	
150	S2-36	896	IPFAMQMAYRFN	907	
151	S2_37	002	MAYRENGIGVTO	013	
101	52-57	302		315	
152	S2-38	908	GIGVTQNVLYEN	919	
152	62.20	014		0.25	
155	32-39	914	INVETENQALIAN	925	
154	S2-40	920	QKLIANQFNSAI	931	
155	SO 11	0.26	OENSAICKIODS	027	
155	32-41	920	QFNSAIGNIQDS	937	
156	S2-42	932	GKIQDSLSSTAS	943	
457	CO 40	000		0.40	
157	52-43	938	LSSTASALGKLQ	949	
158	S2-44	944	ALGKLODVVNON	955	
450	00.45	050		004	
159	52-45	950	DVVNQNAQALNI	961	
160	S2-46	956	AQAI NTI VKQI S	967	
404	00.47	000		070	
161	S2-47	962	LVKQLSSNFGAI	973	
162	S2-48	968	SNEGAISSV/LND	979	
102	02-40	500		515	
163	S2-49	974	SSVLNDILSRLD	985	
16/	\$2-50	080		001	
104	52-50	300		331	
165	S2-51	986	KVEAEVQIDRLI	997	
166	S2 52	002		1003	
100	32-32	992	QIDITELLORITOREQO	1005	
167	S2-53	998	TGRLQSLQTYVT	1009	
160	S2 54	1004		1015	
100	52-54	1004	LQTYVIQQLIKA	1015	
169	S2-55	1010	QQLIRAAEIRAS	1021	
170	00.50	1010		4007	
170	52-50	1016	AEIRASANLAAT	1027	
171	S2-57	1022	ANLAATKMSECV	1033	
470	00 50	1000		1000	
172	52-58	1028	KMSECVLGQSKR	1039	
173	S2-59	1034	I GOSKRVDECGK	1045	
170	02 00	1001		1010	
1/4	S2-60	1040	VDFCGKGYHLMS	1051	
175	S2-61	1046	GYHI MSEPOSAP	1057	
170	02 01	1040		1007	
1/6	S2-62	1052	FPQSAPHGVVFL	1063	
177	S2-63	1058	HGV/VELHV/TVVP	1069	
177	02-00	1000		1005	
178	S2-64	1064	HVTYVPAQEKNF	1075	
170	\$2-65	1070	ΔΟΕΚΝΕΤΤΔΡΔΙ	1081	
179	32-03	1070	AQENNETTAFAI	1001	
180	S2-66	1076	TTAPAICHDGKA	1087	
101	S2 67	1092	CUDCKAUEDDEC	1002	
101	32-07	1002	CHUGKAHFFREG	1095	
182	S2-68	1088	HEPREGVEVSNG	1099	
102	02 00	1000		1000	
183	S2-69	1094	VEVSNGTHWEVT	1105	
184	S2-70	1100	THWEVTORNEYE	1111	
104	02 70	1100			
185	S2-71	1106	QRNFYEPQIIII	1117	
186	S2-72	1112	POUTTONTEVS	1123	
100	02 72	1112		1120	
187	S2-73	1118	DNTFVSGNCDVV	1129	
188	S2-74	1124	GNCDV//IGIV/NN	1135	Failure for synthesis
100	02-14	1124		1100	1 andre for Synthesis
189	S2-75	1130	IGIVNNTVYDPL	1141	
100	S2-76	1136		11/7	
130	52-70	1150		1147	
191	S2-77	1142	QPELDSFKEELD	1153	
102	CO 70	1110		1150	
192	32-70	1140	FREELDRIFRING	1159	
193	S2-79	1154	KYFKNHTSPDVD	1165	
104	62.00	1100		1171	
194	52-00	1160	I SPDVDLGDISG	11/1	
195	S2-81	1166	LGDISGINASVV	1177	
400	00.00	1170		1100	
196	52-82	1172	INASVVNIQKEI	1183	
197	S2-83	1178	NIQKEIDRI NEV	1189	
400	00.04	1101		4405	
198	S2-84	1184	DRLNEVAKNLNE	1195	
100	\$2-85	1190	AKNI NESLIDI O	1201	
100	02-00	1100		1201	
200	S2-86	1196	SLIDLQELGKYE	1207	
201	S2 87	1202		1013	
201	32-01	1202	ELGRIEQTINVE	1213	
202	S2-88	1208	QYIKWPWYIWLG	1219	
202	S2 00	1014		1225	Eailura for aunthoaia
203	32-09	1214	WHWLGFIAGLI	1220	anure for synthesis
204	S2-90	1220	FIAGLIAIVMVT	1231	Failure for synthesis
205	62.04	1000		1007	Collura for synthesis
205	52-91	1226	AIVINIVITIMLCCM	1237	Failure for synthesis
206	S2-92	1232	IMI COMTSCOSC	1243	Failure for synthesis
200	00.02	1202	T00000 K0000	1010	
207	52-93	1238	TSUUSULKGUUS	1249	
208	S2-94	1244	LKGCCSCGSCCK	1255	Insoluble
200	02-04	1277		1200	modubic
209	S2-95	1250	CGSCCKFDEDDS	1261	
210	52-96	1256	EDEDDSEP\/LKG	1267	
210	02-30	1200		1201	
0 4 4	00 07	1000			

SARS-CoV-2 p	n=55		
Condor	Male	27	
Gender	Female	28	
Ag	Age		
Coverity	mild cases	8	
Seventy	moderate cases	47	
Days after onset		27.5±7.7	
hospital stay (days)		14.0±5.6	
Non-infection	control group	n=18	
Lung cancer patients (LC)		9	
Health control (HC)		9	
Quardan	Male	8	
Gender	Female	10	
Age		50.4±12.5	
Sample collection (year)		2017-2018	

Extended Data Table 2. Serum samples used in this study